1368488
2022
1
heidelberg-university-faculty-of-medicine
50
creator
asc
year
1
241
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%223996TQSC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%2C%20Sammarco%20Rosa%2C%20P.%2C%20Chauffour%2C%20A.%2C%20Fletcher%2C%20M.%20L.%2C%20Cambau%2C%20E.%20and%20Avanzi%2C%20C.%20%282022%29.%20%3Cb%3EDrug%20resistance%20in%20leprosy%3A%20An%20update%20following%2070years%20of%20chemotherapy%3C%5C%2Fb%3E.%20Infectious%20Diseases%20Now%20%3Ci%3E52%3C%5C%2Fi%3E%2C%20243%26%23x2013%3B251%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2022.04.001%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.idnow.2022.04.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Drug%20resistance%20in%20leprosy%3A%20An%20update%20following%2070years%20of%20chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Sammarco%20Rosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Chauffour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20L.%22%2C%22lastName%22%3A%22Fletcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Avanzi%22%7D%5D%2C%22abstractNote%22%3A%22Leprosy%20is%20one%20of%20the%20oldest%20infectious%20diseases%2C%20reported%20for%20more%20than%202000years.%20Leprosy%20elimination%20goal%20as%20a%20public%20health%20problem%20set%20by%20the%20World%20Health%20Organization%2C%20aiming%20for%20a%20global%20prevalence%20rate%3C1%20patient%20in%20a%20population%20of%2010%2C000%2C%20was%20achieved%20in%202000%20mainly%20thanks%20to%20the%20worldwide%20use%20of%20leprosy%20drugs%20starting%20in%20the%201980s%20and%20their%20access%20at%20no%20cost%20for%20patients%20since%201995.%20However%2C%20around%20200%2C000%20new%20cases%20are%20still%20reported%20each%20year%2C%20particularly%20in%20India%2C%20Brazil%2C%20and%20Indonesia.%20As%20with%20other%20bacteria%20of%20medical%20interest%2C%20antimicrobial%20resistance%20is%20observed%20in%20Mycobacterium%20leprae%20strains%20in%20several%20parts%20of%20the%20world%2C%20despite%20multidrug%20therapy%20being%20the%20recommended%20standard%20leprosy%20treatment%20to%20avoid%20resistance%20selection%20since%201982.%20Therefore%2C%20identifying%20and%20monitoring%20resistance%20is%20necessary.%20We%20provide%20an%20overview%20of%20the%20historical%20facts%20that%20led%20to%20the%20current%20drug%20resistance%20situation%2C%20the%20antibiotics%20effective%20against%20M.%5Cu00a0leprae%2C%20their%20mechanisms%20of%20action%20and%20resistance%2C%20and%20resistance%20detection%20methods.%20We%20also%20discuss%20therapeutic%20management%20of%20the%20resistant%20cases%2C%20new%20genes%20with%20potential%20roles%20in%20drug%20resistance%20and%20bacterial%20adaptation%2C%20new%20drugs%20under%20investigation%2C%20and%20the%20risk%20for%20resistance%20selection%20with%20the%20chemoprophylaxis%20measures.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.idnow.2022.04.001%22%2C%22ISSN%22%3A%222666-9919%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2666991922000665%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A26%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22PF5DMFLC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bachir%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBachir%2C%20M.%2C%20Guglielmetti%2C%20L.%2C%20Tunesi%2C%20S.%2C%20Billard-Pomares%2C%20T.%2C%20Chiesi%2C%20S.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Langris%2C%20H.%2C%20Pourcher%2C%20V.%2C%20Schramm%2C%20F.%2C%20Lema%26%23xEE%3Btre%2C%20N.%20and%20Robert%2C%20J.%20%282022%29.%20%3Cb%3EMolecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%3C%5C%2Fb%3E.%20Journal%20of%20Infection%20%3Ci%3E85%3C%5C%2Fi%3E%2C%2024%26%23x2013%3B30%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.05.017%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20detection%20of%20isoniazid%20monoresistance%20improves%20tuberculosis%20treatment%3A%20A%20retrospective%20cohort%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marwa%22%2C%22lastName%22%3A%22Bachir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Typhaine%22%2C%22lastName%22%3A%22Billard-Pomares%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheila%22%2C%22lastName%22%3A%22Chiesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00e9my%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Langris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Schramm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lema%5Cu00eetre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnIsoniazid-monoresistant%20tuberculosis%20%28HR-TB%29%20requires%20early%20diagnosis%20and%20adapted%20treatment%20to%20achieve%20optimal%20outcomes.%20The%20primary%20aim%20of%20the%20study%20was%20to%20assess%20the%20impact%20of%20the%20implementation%20of%20rapid%20diagnostic%20tests%20on%20HR-TB%20treatment%20in%20France.%5CnMethods%5CnWe%20designed%20a%20retrospective%20multicentre%20study%20including%20consecutive%20HR-TB%20patients%20diagnosed%20in%202016%20and%202017.%20Implementation%20of%20a%20molecular%20assay%20detecting%20isoniazid%20resistance%20directly%20on%20a%20clinical%20sample%20was%20recorded.%20The%20association%20between%20early%20implementation%20of%20such%20assays%20and%20adequate%20treatment%20was%20assessed%20by%20a%20multivariable%20Cox%20proportional%20hazards%20model.%5CnResults%5CnOverall%2C%2099%20HR-TB%20patients%20were%20included%20from%2020%20University%20Hospitals.%20Among%20all%20smear-positive%20HR-TB%20patients%2C%20only%2026%25%20beneficiated%20from%20early%20molecular%20HR%20detection.%20This%20detection%20was%20independently%20associated%20with%20shorter%20time%20to%20adequate%20treatment%20%28HR%5Cu00a0%3D%5Cu00a02.0%20%5B1.1%5Cu20133.8%5D%2C%20p%5Cu00a0%3D%5Cu00a00.03%29.%5CnConclusion%5CnIn%20our%20study%2C%20molecular%20detection%20of%20HR%20on%20an%20initial%20sample%20was%20independently%20associated%20with%20earlier%20treatment%20adaptation.%22%2C%22date%22%3A%222022-07-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.05.017%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0163445322003061%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A19%3A23Z%22%7D%7D%2C%7B%22key%22%3A%22HUBVTWEL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bonnet%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-14%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBonnet%2C%20I.%2C%20Haddad%2C%20E.%2C%20Guglielmetti%2C%20L.%2C%20B%26%23xE9%3Bmer%2C%20P.%2C%20Bernard%2C%20L.%2C%20Bourgoin%2C%20A.%2C%20Brault%2C%20R.%2C%20Catho%2C%20G.%2C%20Caumes%2C%20E.%2C%20Escaut%2C%20L.%2C%20Fourniols%2C%20E.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Gaudart%2C%20A.%2C%20Guillot%2C%20H.%2C%20Lafon-Desmurs%2C%20B.%2C%20Lanoix%2C%20J.-P.%2C%20Lanotte%2C%20P.%2C%20Lemaignen%2C%20A.%2C%20Lemaire%2C%20B.%2C%20Lemaitre%2C%20N.%2C%20Michau%2C%20C.%2C%20Morand%2C%20P.%2C%20Mougari%2C%20F.%2C%20Marigot-Outtandy%2C%20D.%2C%20Patrat-Delon%2C%20S.%2C%20Perpoint%2C%20T.%2C%20Piau%2C%20C.%2C%20Pourcher%2C%20V.%2C%20Zarrouk%2C%20V.%2C%20Zeller%2C%20V.%2C%20Veziris%2C%20N.%2C%20Jaur%26%23xE9%3Bguiberry%2C%20S.%20and%20Aubry%2C%20A.%20%282022%29.%20%3Cb%3EClinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201215%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10061215%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20Features%20and%20Outcome%20of%20Multidrug-Resistant%20Osteoarticular%20Tuberculosis%3A%20A%2012-Year%20Case%20Series%20from%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Haddad%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22B%5Cu00e9mer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bourgoin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%22%2C%22lastName%22%3A%22Brault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaud%22%2C%22lastName%22%3A%22Catho%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L%5Cu00e9lia%22%2C%22lastName%22%3A%22Escaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Fourniols%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Gaudart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barth%5Cu00e9l%5Cu00e9my%22%2C%22lastName%22%3A%22Lafon-Desmurs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Lanoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Lanotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Lemaignen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Lemaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadine%22%2C%22lastName%22%3A%22Lemaitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Michau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Morand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Patrat-Delon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Perpoint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Piau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Zarrouk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Zeller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Jaur%5Cu00e9guiberry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22The%20optimal%20treatment%20for%20osteoarticular%20infection%20due%20to%20multidrug-resistant%20tuberculosis%20strains%20%28MDR-OATB%29%20remains%20unclear.%20This%20study%20aims%20to%20evaluate%20the%20diagnosis%2C%20management%20and%20outcome%20of%20MDR-OATB%20in%20France.%20We%20present%20a%20case%20series%20of%20MDR-OATB%20patients%20reviewed%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20between%202007%20and%202018.%20Medical%20history%20and%20clinical%2C%20microbiological%2C%20treatment%20and%20outcome%20data%20were%20collected.%20Twenty-three%20MDR-OATB%20cases%20were%20reported%2C%20representing%203%25%20of%20all%20concurrent%20MDR-TB%20cases%20in%20France.%20Overall%2C%2017%20were%20male%2C%20and%20the%20median%20age%20was%2032%20years.%20Six%20patients%20were%20previously%20treated%20for%20TB%2C%20including%20four%20with%20first-line%20drugs.%20The%20most%20frequently%20affected%20site%20was%20the%20spine%20%28n%20%3D%2016%29.%20Bone%20and%20joint%20surgery%20were%20required%20in%2012%20patients.%20Twenty-one%20patients%20%2891%25%29%20successfully%20completed%20the%20treatment%20with%20a%20regimen%20containing%20a%20mean%20of%20four%20drugs%20%28range%2C%202%5Cu20136%29%20for%20a%20mean%20duration%20of%2020%20months%20%28range%2C%2013%5Cu201327%29.%20Overall%2C%20high%20rates%20of%20treatment%20success%20were%20achieved%20following%20WHO%20MDR-TB%20treatment%20guidelines%20and%20individualized%20patient%20management%20recommendations%20by%20the%20French%20National%20TB%20Consilium.%20However%2C%20the%20optimal%20combination%20of%20drugs%2C%20duration%20of%20treatment%20and%20role%20of%20surgery%20in%20the%20management%20of%20MDR-OATB%20remains%20to%20be%20determined.%22%2C%22date%22%3A%222022-6-14%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10061215%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9229793%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A21%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22AM4AMZDJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chaptal%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChaptal%2C%20M.%2C%20Andrejak%2C%20C.%2C%20Bonifay%2C%20T.%2C%20Beillard%2C%20E.%2C%20Guillot%2C%20G.%2C%20Guyomard-Rabenirina%2C%20S.%2C%20Demar%2C%20M.%2C%20Trombert-Paolantoni%2C%20S.%2C%20Jacomo%2C%20V.%2C%20Mosnier%2C%20E.%2C%20Veziris%2C%20N.%2C%20Djossou%2C%20F.%2C%20Epelboin%2C%20L.%20and%20Group%2C%20F.%20G.%20P.%20working%20%282022%29.%20%3Cb%3EEpidemiology%20of%20infection%20by%20pulmonary%20non-tuberculous%20mycobacteria%20in%20French%20Guiana%202008%26%23x2013%3B2018%3C%5C%2Fb%3E.%20PLOS%20Neglected%20Tropical%20Diseases%20%3Ci%3E16%3C%5C%2Fi%3E%2C%20e0010693%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0010693%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pntd.0010693%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epidemiology%20of%20infection%20by%20pulmonary%20non-tuberculous%20mycobacteria%20in%20French%20Guiana%202008%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mil%5Cu00e8ne%22%2C%22lastName%22%3A%22Chaptal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timoth%5Cu00e9e%22%2C%22lastName%22%3A%22Bonifay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Beillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Guyomard-Rabenirina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Demar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Trombert-Paolantoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Jacomo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Mosnier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felix%22%2C%22lastName%22%3A%22Djossou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Epelboin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22French%20Guiana%20PNTM%20working%22%2C%22lastName%22%3A%22Group%22%7D%5D%2C%22abstractNote%22%3A%22Introduction%20Unlike%20diseases%20caused%20by%20Mycobacterium%20tuberculosis%2C%20M.%20leprae%20and%20M.%20ulcerans%2C%20the%20epidemiology%20of%20pulmonary%20non-tuberculous%20mycobacteria%20%28PNTM%29%20has%20not%20received%20due%20attention%20in%20French%20Guiana.%20The%20main%20objective%20of%20the%20current%20study%20was%20to%20define%20the%20incidence%20of%20these%20PNTM%20infections%3A%20NTM%20pulmonary%20diseases%20%28NTM-PD%29%20and%20casual%20PNTM%20isolation%20%28responsible%20of%20latent%20infection%20or%20simple%20colonization%29.%20The%20secondary%20objectives%20were%20to%20determine%20species%20diversity%20and%20geographic%20distribution%20of%20these%20atypical%20mycobacteria.%20Methods%20A%20retrospective%20observational%20study%20%282008%5Cu20132018%29%20of%20French%20Guiana%20patients%20with%20at%20least%20one%20PNTM%20positive%20respiratory%20sample%20in%20culture%20was%20conducted.%20Patients%20were%20then%20classified%20into%20two%20groups%3A%20casual%20PNTM%20isolation%20or%20pulmonary%20disease%20%28NTM-PD%29%2C%20according%20to%20clinical%2C%20radiological%20and%20microbiological%20criteria%20defined%20by%20the%20American%20Thoracic%20Society%20%5C%2F%20Infectious%20Disease%20Society%20of%20America%20%28ATS%20%5C%2F%20IDSA%29%20in%202007.%20Results%20178%20patients%20were%20included%2C%20out%20of%20which%20147%20had%20casual%20PNTM%20isolation%20and%2031%20had%20NTM-PD.%20Estimated%20annual%20incidence%20rate%20of%20respiratory%20isolates%20was%206.17%20%5C%2F%20100%2C000%20inhabitants%20per%20year%20while%20that%20of%20NTM-PD%20was%201.07%20%5C%2F%20100%2C000%20inhabitants%20per%20year.%20Among%20the%20178%20patients%2C%20M.%20avium%20complex%20%28MAC%29%20was%20the%20most%20frequently%20isolated%20pathogen%20%2838%25%29%2C%20followed%20by%20M.%20fortuitum%20then%20M.%20abscessus%20%2819%25%20and%206%25%20of%20cases%20respectively%29%2C%20the%20latter%20two%20mycobacteria%20being%20mainly%20found%20in%20the%20coastal%20center%20region.%20Concerning%20NTM-PD%2C%20two%20species%20were%20mainly%20involved%3A%20MAC%20%2881%25%29%20and%20M.%20abscessus%20%2816%25%29.%20Discussion%5C%2FConclusion%20This%20is%20the%20first%20study%20on%20the%20epidemiology%20of%20PNTM%20infections%20in%20French%20Guiana.%20PNTM%5Cu2019s%20incidence%20looks%20similar%20to%20other%20contries%20and%20metropolitan%20France%20and%20NTM-PD%20is%20mostly%20due%20to%20MAC%20and%20M.abscessus.%20Although%20French%20Guiana%20is%20the%20French%20territory%20with%20the%20highest%20tuberculosis%20incidence%2C%20NTM%20should%20not%20be%20overlooked.%22%2C%22date%22%3A%229%20sept.%202022%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pntd.0010693%22%2C%22ISSN%22%3A%221935-2735%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosntds%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pntd.0010693%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A15%3A19Z%22%7D%7D%2C%7B%22key%22%3A%22THH9Q9E6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chiron%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EChiron%2C%20R.%2C%20Hoefsloot%2C%20W.%2C%20Van%20Ingen%2C%20J.%2C%20Marchandin%2C%20H.%2C%20Kremer%2C%20L.%2C%20Morisse-Pradier%2C%20H.%2C%20Charriot%2C%20J.%2C%20Mallet%2C%20J.-P.%2C%20Herrmann%2C%20J.-L.%2C%20Caimmi%2C%20D.%2C%20Moreau%2C%20J.%2C%20Dumont%2C%20Y.%2C%20Godreuil%2C%20S.%2C%20Bergeron%2C%20A.%2C%20Drevait%2C%20M.%2C%20Bouzat-Rossigneux%2C%20E.%2C%20Terrail%2C%20N.%2C%20Andrejak%2C%20C.%2C%20Veziris%2C%20N.%2C%20Grenet%2C%20D.%2C%20Coudrat%2C%20A.%20and%20Catherinot%2C%20E.%20%282022%29.%20%3Cb%3EAmikacin%20Liposomal%20Inhalation%20Suspension%20in%20the%20Treatment%20of%20Mycobacterium%20abscessus%20Lung%20Infection%3A%20A%20French%20Observational%20Experience%3C%5C%2Fb%3E.%20Open%20Forum%20Infect%20Dis%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac465%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac465%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac465%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Amikacin%20Liposomal%20Inhalation%20Suspension%20in%20the%20Treatment%20of%20Mycobacterium%20abscessus%20Lung%20Infection%3A%20A%20French%20Observational%20Experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Chiron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wouter%22%2C%22lastName%22%3A%22Hoefsloot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22Van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Marchandin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Kremer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Morisse-Pradier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%22%2C%22lastName%22%3A%22Charriot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Mallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Davide%22%2C%22lastName%22%3A%22Caimmi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johan%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Dumont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Godreuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bergeron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margot%22%2C%22lastName%22%3A%22Drevait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Bouzat-Rossigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Terrail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Grenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Coudrat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Catherinot%22%7D%5D%2C%22abstractNote%22%3A%22A%20French%20observational%20cohort%20study%20investigated%20amikacin%20liposome%20inhaled%20suspension%20as%20an%20adjunct%20to%20antibiotic%20regimen%20for%20M%20abscessus%20lung%20infection.%20Sputum%20culture%20conversion%20was%20achieved%20in%2054%25%20%2814%5C%2F26%29%20of%20patients%20with%20acceptable%20safety%20profile%20after%206%20months%20of%20treatment.%22%2C%22date%22%3A%222022-9-11%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac465%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9578164%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A03%3A48Z%22%7D%7D%2C%7B%22key%22%3A%22EBWEL99Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daniau%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDaniau%2C%20C.%2C%20Lecorche%2C%20E.%2C%20Mougari%2C%20F.%2C%20Benmansour%2C%20H.%2C%20Bernet%2C%20C.%2C%20Blanchard%2C%20H.%2C%20Robert%2C%20J.%2C%20Berger-Carbonne%2C%20A.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EAssociation%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%26%23x2012%3B2020%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%20518%26%23x2013%3B526%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2803.211791%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2803.211791%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%5Cu20122020%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00f4me%22%2C%22lastName%22%3A%22Daniau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Lecorche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hanaa%22%2C%22lastName%22%3A%22Benmansour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Bernet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Blanchard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Berger-Carbonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22We%20describe%20nontuberculous%20mycobacteria%20%28NTM%29%20infections%20during%202012%5Cu20132020%20associated%20with%20health%20care%20and%20aesthetic%20procedures%20in%20France.%20We%20obtained%20epidemiologic%20data%20from%20the%20national%20early%20warning%20response%20system%20for%20healtcare-associated%20infections%20and%20data%20on%20NTM%20isolates%20from%20the%20National%20Reference%20Center%20for%20Mycobacteria.%20We%20compared%20clinical%20and%20environmental%20isolates%20by%20using%20whole-genome%20sequencing.%20The%2085%20original%20cases%20were%20reported%20after%20surgery%20%2848%2C%2056%25%29%2C%20other%20invasive%20procedures%20%2828%2C%2033%25%29%20and%20other%20procedures%20%289%2C%2011%25%29.%20NTM%20isolates%20belonged%20to%20rapidly%20growing%20%2873%2C%2086%25%29%20and%20slowly%20growing%20%2810%2C%2012%25%29%20species%3B%20in%202%20cases%2C%20the%20species%20was%20not%20identified.%20We%20performed%20environmental%20investigations%20for%2038%20%2845%25%29%20cases%3B%20results%20for%2012%20%2832%25%29%20were%20positive%20for%20the%20same%20NTM%20species%20as%20for%20the%20infection.%20In%2010%20cases%20that%20had%20environmental%20and%20clinical%20samples%20whose%20genomes%20were%20similar%2C%20the%20infection%20source%20was%20probably%20the%20water%20used%20in%20the%20procedures.%20NTM%20infections%20could%20be%20preventable%20by%20using%20sterile%20water%20in%20all%20invasive%20procedures.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2803.211791%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8888244%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T21%3A35%3A04Z%22%7D%7D%2C%7B%22key%22%3A%22FXY3SR7C%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daniau%20et%20al.%22%2C%22parsedDate%22%3A%222022-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDaniau%2C%20C.%2C%20Berger-Carbonne%2C%20A.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EAssociation%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%26%23x2012%3B2020%20%28response%29%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201303%26%23x2013%3B1304%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2806.220686%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2806.220686%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Association%20of%20Healthcare%20and%20Aesthetic%20Procedures%20with%20Infections%20Caused%20by%20Nontuberculous%20Mycobacteria%2C%20France%2C%202012%5Cu20122020%20%28response%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00f4me%22%2C%22lastName%22%3A%22Daniau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Berger-Carbonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-6%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2806.220686%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9155901%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A15Z%22%7D%7D%2C%7B%22key%22%3A%2232L5JEUW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Castro%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Castro%2C%20N.%2C%20Mecha%26%23xEF%3B%2C%20F.%2C%20Bachelet%2C%20D.%2C%20Canestri%2C%20A.%2C%20Joly%2C%20V.%2C%20Vandenhende%2C%20M.%2C%20Boutoille%2C%20D.%2C%20Kerjouan%2C%20M.%2C%20Veziris%2C%20N.%2C%20Molina%2C%20J.%20M.%2C%20Grall%2C%20N.%2C%20Tattevin%2C%20P.%2C%20Laou%26%23xE9%3Bnan%2C%20C.%2C%20Yazdanpanah%2C%20Y.%20and%20for%20the%20FAST%20TB%20Study%20Group%20%282022%29.%20%3Cb%3ETreatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%3C%5C%2Fb%3E.%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E9%3C%5C%2Fi%3E%2C%20ofac353%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Treatment%20With%20a%20Three-Drug%20Regimen%20for%20Pulmonary%20Tuberculosis%20Based%20on%20Rapid%20Molecular%20Detection%20of%20Isoniazid%20Resistance%3A%20A%20Noninferiority%20Randomized%20Trial%20%28FAST-TB%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22De%20Castro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mecha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Bachelet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A%22%2C%22lastName%22%3A%22Canestri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%22%2C%22lastName%22%3A%22Joly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Vandenhende%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D%22%2C%22lastName%22%3A%22Boutoille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%22%2C%22lastName%22%3A%22Kerjouan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%20M%22%2C%22lastName%22%3A%22Molina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N%22%2C%22lastName%22%3A%22Grall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P%22%2C%22lastName%22%3A%22Tattevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Laou%5Cu00e9nan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20FAST%20TB%20Study%20Group%22%7D%5D%2C%22abstractNote%22%3A%22The%20rationale%20behind%20the%20use%20of%20ethambutol%20in%20the%20standard%20tuberculosis%20treatment%20is%20to%20prevent%20the%20emergence%20of%20resistance%20to%20rifampicin%20in%20case%20of%20primary%20resistance%20to%20isoniazid.%20We%20evaluated%20whether%20early%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%20allows%20the%20use%20an%20ethambutol-free%20regimen.FAST-TB%2C%20a%20phase%204%2C%20French%2C%20multicenter%2C%20open-label%2C%20non-inferiority%20trial%2C%20compared%202%20strategies%3A%20%281%29%20polymerase%20chain%20reaction%20%28PCR%29-based%20detection%20of%20isoniazid%20and%20rifampicin%20resistance%20at%20baseline%20using%20Genotype%20MTBDRplus%20version%202.0%20followed%20by%20ethambutol%20discontinuation%20if%20no%20resistance%20was%20detected%20%28PCR%20arm%29%20and%20%282%29%20a%20standard%204-drug%20combination%2C%20pending%20phenotypic%20drug-susceptibility%20results%20%28C%20arm%29.%20Adult%20patients%20with%20smear-positive%20pulmonary%20tuberculosis%20were%20enrolled.%20The%20primary%20endpoint%20was%20the%20proportion%20of%20patients%20with%20treatment%20success%20defined%20as%20bacteriological%20or%20clinical%20cure%20at%20the%20end%20of%20treatment.%20A%20non-inferiority%20margin%20of%2010%25%20was%20used.Two%20hundred%20three%20patients%20were%20randomized%2C%20104%20in%20the%20PCR%20arm%20and%2099%20in%20the%20C%20arm%3A%2026.6%25%20were%20female%2C%20median%20age%20was%2037%20%28interquartile%20range%2C%2028%5Cu201351%29%20years%2C%2072.4%25%20were%20born%20in%20Africa%2C%20and%205.4%25%20were%20infected%20with%20human%20immunodeficiency%20virus.%20Chest%20x-ray%20showed%20cavities%20in%2064.5%25%20of%20the%20cases.%20Overall%2C%20169%20patients%20met%20criteria%20of%20treatment%20success%3A%2087%20of%20104%20%2883.7%25%29%20in%20the%20PCR%20arm%20and%2082%20of%2099%20%2882.8%25%29%20in%20the%20C%20arm%20with%20a%20difference%20of%20%2B0.8%25%20%2890%25%20confidence%20interval%2C%20%5Cu22127.9%20to%209.6%29%2C%20meeting%20the%20noninferiority%20criteria%20in%20the%20intention-to-treat%20population%20%28P%5Cu2009%3D%5Cu2009.02%29.In%20a%20setting%20with%20low%20prevalence%20of%20primary%20isoniazid%20resistance%2C%20a%203-drug%20combination%20with%20isoniazid%2C%20rifampicin%2C%20and%20pyrazinamide%2C%20based%20on%20rapid%20detection%20of%20isoniazid%20resistance%20using%20molecular%20testing%2C%20was%20noninferior%20to%20starting%20the%20recommended%204-drug%20regimen.%22%2C%22date%22%3A%222022-08-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofac353%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofac353%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A20%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22S6JQ4XIX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Eimer%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-19%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EEimer%2C%20J.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Caumes%2C%20E.%2C%20El-Helali%2C%20N.%2C%20Marigot-Outtandy%2C%20D.%2C%20Mechai%2C%20F.%2C%20Peytavin%2C%20G.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20Robert%2C%20J.%2C%20Guglielmetti%2C%20L.%20and%20for%20the%20LZDM%20group%20%282022%29.%20%3Cb%3EIncreased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%3C%5C%2Fb%3E%20Clinical%20Infectious%20Diseases%20ciac485%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Increased%20linezolid%20plasma%20concentrations%20are%20associated%20with%20the%20development%20of%20severe%20toxicity%20in%20MDR-TB%20treatment.%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johannes%22%2C%22lastName%22%3A%22Eimer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Najoua%22%2C%22lastName%22%3A%22El-Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhiba%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Mechai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gilles%22%2C%22lastName%22%3A%22Peytavin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22for%20the%20LZDM%20group%22%7D%5D%2C%22abstractNote%22%3A%22Treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20with%20linezolid%20is%20characterized%20by%20high%20rates%20of%20adverse%20events.%20Evidence%20on%20therapeutic%20drug%20monitoring%20to%20predict%20drug%20toxicity%20is%20scarce.%20This%20study%20aimed%20to%20evaluate%20the%20association%20of%20linezolid%20trough%20concentrations%20with%20severe%20toxicity.We%20retrospectively%20assessed%20consecutive%20patients%20started%20on%20linezolid%20for%20MDR-TB%20between%202011%20and%202017.%20The%20primary%20outcome%20was%20severe%20mitochondrial%20toxicity%20%28SMT%29%20due%20to%20linezolid%2C%20defined%20as%20neurotoxicity%20or%20myelotoxicity%20leading%20to%20drug%20discontinuation.%20The%20impact%20of%20plasma%20linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20assessed%20in%20multivariate%20Cox%20proportional%20hazards%20models%20including%20time-varying%20covariates.SMT%20occurred%20in%2057%20of%20146%20included%20patients%20%2839%25%29%20at%20an%20incidence%20rate%20of%200.38%20per%20person-year%20%2895%25CI%200.30-0.49%29.%20A%20maximum%20linezolid%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20was%20detected%20in%2052%20patients%20%2835.6%25%29%2C%20while%20the%20mean%20trough%20concentration%20was%20%26gt%3B2%5Cu2005mg%5C%2FL%20in%2022%20%2815%25%29.%20The%20adjusted%20hazard%20ratio%20for%20SMT%20was%202.35%20%2895%25CI%201.26%5Cu20134.38%2C%20p%5Cu2009%3D%5Cu20090.01%29%20in%20patients%20with%20a%20mean%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL%20and%202.63%20%2895%25CI%201.55%5Cu20134.47%2C%20p%5Cu2009%26lt%3B%5Cu20090.01%29%20for%20SMT%20after%20the%20first%20detection%20of%20a%20trough%20concentration%20%26gt%3B2%5Cu2005mg%5C%2FL.%20In%20an%20exploratory%20analysis%2C%20higher%20maximum%20trough%20concentrations%20were%20dose-dependently%20associated%20with%20toxicity%2C%20while%20lowering%20of%20elevated%20trough%20concentrations%20did%20not%20restore%20baseline%20risk.Linezolid%20trough%20concentrations%20%26gt%3B2%5Cu2005mg%5C%2FL%20are%20strongly%20associated%20with%20the%20development%20of%20severe%20treatment-emergent%20toxicity%20in%20patients%20treated%20for%20MDR-TB.%20Pending%20further%20prospective%20evidence%2C%20an%20individual%20risk-benefit%20assessment%20on%20the%20continuation%20of%20linezolid%20treatment%20is%20warranted%20in%20any%20patient%20with%20trough%20concentrations%20above%202%5Cu2005mg%5C%2FL.%22%2C%22date%22%3A%222022-06-19%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac485%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac485%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-08T13%3A02%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22QDAG4PLL%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Group%20et%20al.%22%2C%22parsedDate%22%3A%222022-04-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGroup%2C%20A.%20S.%20T.%2C%20Georghiou%2C%20S.%20B.%2C%20Rodwell%2C%20T.%20C.%2C%20Korobitsyn%2C%20A.%2C%20Abbadi%2C%20S.%20H.%2C%20Ajbani%2C%20K.%2C%20Alffenaar%2C%20J.-W.%2C%20Alland%2C%20D.%2C%20Alvarez%2C%20N.%2C%20Andres%2C%20S.%2C%20Ardizzoni%2C%20E.%2C%20Aubry%2C%20A.%2C%20Baldan%2C%20R.%2C%20Ballif%2C%20M.%2C%20Barilar%2C%20I.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Chakravorty%2C%20S.%2C%20Claxton%2C%20P.%20M.%2C%20Cirillo%2C%20D.%20M.%2C%20Comas%2C%20I.%2C%20Coulter%2C%20C.%2C%20Denkinger%2C%20C.%20M.%2C%20Derendinger%2C%20B.%2C%20Desmond%2C%20E.%20P.%2C%20Steenwinkel%2C%20J.%20E.%20M.%20de%2C%20Dheda%2C%20K.%2C%20Diacon%2C%20A.%20H.%2C%20Dolinger%2C%20D.%20L.%2C%20Dooley%2C%20K.%20E.%2C%20Egger%2C%20M.%2C%20Ehsani%2C%20S.%2C%20Farhat%2C%20M.%20R.%2C%20Fattorini%2C%20L.%2C%20Finci%2C%20I.%2C%20Ray%2C%20L.%20F.%20L.%2C%20Furi%26%23xF3%3B%2C%20V.%2C%20Groenheit%2C%20R.%2C%20Gumbo%2C%20T.%2C%20Heysell%2C%20S.%20K.%2C%20Hillemann%2C%20D.%2C%20Hoffmann%2C%20H.%2C%20Hsueh%2C%20P.-R.%2C%20Hu%2C%20Y.%2C%20Huang%2C%20H.%2C%20Hussain%2C%20A.%2C%20Ismail%2C%20F.%2C%20Izumi%2C%20K.%2C%20Jagielski%2C%20T.%2C%20Johnson%2C%20J.%20L.%2C%20Kambli%2C%20P.%2C%20Kaniga%2C%20K.%2C%20Karunaratne%2C%20G.%20H.%20R.%20E.%2C%20Sharma%2C%20M.%20K.%2C%20Keller%2C%20P.%20M.%2C%20Kelly%2C%20E.%20C.%2C%20Kholina%2C%20M.%2C%20Kohli%2C%20M.%2C%20Kranzer%2C%20K.%2C%20Laurenson%2C%20I.%20F.%2C%20Limberis%2C%20J.%2C%20Lin%2C%20S.-Y.%20G.%2C%20Liu%2C%20Y.%2C%20L%26%23xF3%3Bpez-Gav%26%23xED%3Bn%2C%20A.%2C%20Lyander%2C%20A.%2C%20Machado%2C%20D.%2C%20Martinez%2C%20E.%2C%20Masood%2C%20F.%2C%20Mitarai%2C%20S.%2C%20Mvelase%2C%20N.%20R.%2C%20Niemann%2C%20S.%2C%20Nikolayevskyy%2C%20V.%2C%20Maurer%2C%20F.%20P.%2C%20Merker%2C%20M.%2C%20Miotto%2C%20P.%2C%20Omar%2C%20S.%20V.%2C%20Otto-Knapp%2C%20R.%2C%20Palaci%2C%20M.%2C%20Guti%26%23xE9%3Brrez%2C%20J.%20J.%20P.%2C%20Peacock%2C%20S.%20J.%2C%20Peloquin%2C%20C.%20A.%2C%20Perera%2C%20J.%2C%20Pierre-Audigier%2C%20C.%2C%20Pholwat%2C%20S.%2C%20Posey%2C%20J.%20E.%2C%20Prammananan%2C%20T.%2C%20Rigouts%2C%20L.%2C%20Robledo%2C%20J.%2C%20Rockwood%2C%20N.%2C%20Rodrigues%2C%20C.%2C%20Salfinger%2C%20M.%2C%20Schechter%2C%20M.%20C.%2C%20Seifert%2C%20M.%2C%20Sengstake%2C%20S.%2C%20Shinnick%2C%20T.%2C%20Shubladze%2C%20N.%2C%20Sintchenko%2C%20V.%2C%20Sirgel%2C%20F.%2C%20Somasundaram%2C%20S.%2C%20Sterling%2C%20T.%20R.%2C%20Spitaleri%2C%20A.%2C%20Streicher%2C%20E.%2C%20Supply%2C%20P.%2C%20Svensson%2C%20E.%2C%20Tagliani%2C%20E.%2C%20Tahseen%2C%20S.%2C%20Takaki%2C%20A.%2C%20Theron%2C%20G.%2C%20Torrea%2C%20G.%2C%20Deun%2C%20A.%20V.%2C%20Ingen%2C%20J.%20van%2C%20Rie%2C%20A.%20V.%2C%20Soolingen%2C%20D.%20van%2C%20Jr%2C%20R.%20V.%2C%20Venter%2C%20A.%2C%20Veziris%2C%20N.%2C%20Villellas%2C%20C.%2C%20Viveiros%2C%20M.%2C%20Warren%2C%20R.%2C%20Wen%2C%20S.%2C%20Werngren%2C%20J.%2C%20Wilkinson%2C%20R.%20J.%2C%20Yang%2C%20C.%2C%20Y%26%23x131%3Blmaz%2C%20F.%20F.%2C%20Zhang%2C%20T.%2C%20Zimenkov%2C%20D.%2C%20Ismail%2C%20N.%2C%20K%26%23xF6%3Bser%2C%20C.%20U.%20and%20Sch%26%23xF6%3Bn%2C%20T.%20%282022%29.%20%3Cb%3EUpdating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00166-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Updating%20the%20approaches%20to%20define%20susceptibility%20and%20resistance%20to%20anti-tuberculosis%20agents%3A%20implications%20for%20diagnosis%20and%20treatment%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antimycobacterial%20Susceptibility%20Testing%22%2C%22lastName%22%3A%22Group%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophia%20B.%22%2C%22lastName%22%3A%22Georghiou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20C.%22%2C%22lastName%22%3A%22Rodwell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexei%22%2C%22lastName%22%3A%22Korobitsyn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Said%20H.%22%2C%22lastName%22%3A%22Abbadi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kanchan%22%2C%22lastName%22%3A%22Ajbani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan-Willem%22%2C%22lastName%22%3A%22Alffenaar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Alland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nataly%22%2C%22lastName%22%3A%22Alvarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00f6nke%22%2C%22lastName%22%3A%22Andres%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Ardizzoni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossella%22%2C%22lastName%22%3A%22Baldan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Ballif%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Barilar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C.%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soumitesh%22%2C%22lastName%22%3A%22Chakravorty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pauline%20M.%22%2C%22lastName%22%3A%22Claxton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22I%5Cu00f1aki%22%2C%22lastName%22%3A%22Comas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Coulter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20M.%22%2C%22lastName%22%3A%22Denkinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitta%22%2C%22lastName%22%3A%22Derendinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Edward%20P.%22%2C%22lastName%22%3A%22Desmond%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jurriaan%20E.%20M.%20de%22%2C%22lastName%22%3A%22Steenwinkel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%20H.%22%2C%22lastName%22%3A%22Diacon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20L.%22%2C%22lastName%22%3A%22Dolinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kelly%20E.%22%2C%22lastName%22%3A%22Dooley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Egger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soudeh%22%2C%22lastName%22%3A%22Ehsani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maha%20R.%22%2C%22lastName%22%3A%22Farhat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lanfranco%22%2C%22lastName%22%3A%22Fattorini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Iris%22%2C%22lastName%22%3A%22Finci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%20Le%22%2C%22lastName%22%3A%22Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victoria%22%2C%22lastName%22%3A%22Furi%5Cu00f3%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ramona%22%2C%22lastName%22%3A%22Groenheit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawanda%22%2C%22lastName%22%3A%22Gumbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20K.%22%2C%22lastName%22%3A%22Heysell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Doris%22%2C%22lastName%22%3A%22Hillemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harald%22%2C%22lastName%22%3A%22Hoffmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Po-Ren%22%2C%22lastName%22%3A%22Hsueh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hairong%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alamdar%22%2C%22lastName%22%3A%22Hussain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Farzana%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kiyohiko%22%2C%22lastName%22%3A%22Izumi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tomasz%22%2C%22lastName%22%3A%22Jagielski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20L.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Priti%22%2C%22lastName%22%3A%22Kambli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kon%5Cu00e9%22%2C%22lastName%22%3A%22Kaniga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20H.%20R.%20Eranga%22%2C%22lastName%22%3A%22Karunaratne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meenu%20Kaushal%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%20M.%22%2C%22lastName%22%3A%22Keller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ellis%20C.%22%2C%22lastName%22%3A%22Kelly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Margarita%22%2C%22lastName%22%3A%22Kholina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mikashmi%22%2C%22lastName%22%3A%22Kohli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katharina%22%2C%22lastName%22%3A%22Kranzer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%20F.%22%2C%22lastName%22%3A%22Laurenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%22%2C%22lastName%22%3A%22Limberis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.-Y.%20Grace%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yongge%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22L%5Cu00f3pez-Gav%5Cu00edn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Lyander%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diana%22%2C%22lastName%22%3A%22Machado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Martinez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faisal%22%2C%22lastName%22%3A%22Masood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Satoshi%22%2C%22lastName%22%3A%22Mitarai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nomonde%20R.%22%2C%22lastName%22%3A%22Mvelase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Niemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vladyslav%22%2C%22lastName%22%3A%22Nikolayevskyy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Merker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paolo%22%2C%22lastName%22%3A%22Miotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shaheed%20V.%22%2C%22lastName%22%3A%22Omar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Otto-Knapp%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mois%5Cu00e9s%22%2C%22lastName%22%3A%22Palaci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Jos%5Cu00e9%20Palacios%22%2C%22lastName%22%3A%22Guti%5Cu00e9rrez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharon%20J.%22%2C%22lastName%22%3A%22Peacock%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20A.%22%2C%22lastName%22%3A%22Peloquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Perera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Pierre-Audigier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suporn%22%2C%22lastName%22%3A%22Pholwat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22James%20E.%22%2C%22lastName%22%3A%22Posey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Therdsak%22%2C%22lastName%22%3A%22Prammananan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Robledo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Neesha%22%2C%22lastName%22%3A%22Rockwood%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camilla%22%2C%22lastName%22%3A%22Rodrigues%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Max%22%2C%22lastName%22%3A%22Salfinger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcos%20C.%22%2C%22lastName%22%3A%22Schechter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marva%22%2C%22lastName%22%3A%22Seifert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Sengstake%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Shinnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Natalia%22%2C%22lastName%22%3A%22Shubladze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vitali%22%2C%22lastName%22%3A%22Sintchenko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederick%22%2C%22lastName%22%3A%22Sirgel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sulochana%22%2C%22lastName%22%3A%22Somasundaram%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%20R.%22%2C%22lastName%22%3A%22Sterling%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Spitaleri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Streicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elisa%22%2C%22lastName%22%3A%22Tagliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabira%22%2C%22lastName%22%3A%22Tahseen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Akiko%22%2C%22lastName%22%3A%22Takaki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grant%22%2C%22lastName%22%3A%22Theron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriela%22%2C%22lastName%22%3A%22Torrea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armand%20Van%22%2C%22lastName%22%3A%22Deun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%20van%22%2C%22lastName%22%3A%22Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annelies%20Van%22%2C%22lastName%22%3A%22Rie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dick%20van%22%2C%22lastName%22%3A%22Soolingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Roger%20Vargas%22%2C%22lastName%22%3A%22Jr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amour%22%2C%22lastName%22%3A%22Venter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Villellas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Viveiros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robin%22%2C%22lastName%22%3A%22Warren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shu%27an%22%2C%22lastName%22%3A%22Wen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jim%22%2C%22lastName%22%3A%22Werngren%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%20J.%22%2C%22lastName%22%3A%22Wilkinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caie%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%20Ferda%22%2C%22lastName%22%3A%22Y%5Cu0131lmaz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tingting%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danila%22%2C%22lastName%22%3A%22Zimenkov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nazir%22%2C%22lastName%22%3A%22Ismail%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudio%20U.%22%2C%22lastName%22%3A%22K%5Cu00f6ser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sch%5Cu00f6n%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetInappropriately%20high%20breakpoints%20have%20resulted%20in%20systematic%20false-susceptible%20AST%20results%20to%20anti-TB%20drugs.%20MIC%2C%20PK%5C%2FPD%20and%20clinical%20outcome%20data%20should%20be%20combined%20when%20setting%20breakpoints%20to%20minimise%20the%20emergence%20and%20spread%20of%20antimicrobial%20resistance.%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3i43wb6%22%2C%22date%22%3A%222022%5C%2F04%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00166-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F4%5C%2F2200166%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22NH7XCKNV%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20G%26%23xFC%3Bnther%2C%20G.%2C%20Leu%2C%20C.%2C%20Cirillo%2C%20D.%2C%20Duarte%2C%20R.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Goletti%2C%20D.%2C%20Jankovic%2C%20M.%2C%20Kuksa%2C%20L.%2C%20Maurer%2C%20F.%20P.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Tiberi%2C%20S.%2C%20Leth%2C%20F.%20van%2C%20Veziris%2C%20N.%20and%20Lange%2C%20C.%20%282022%29.%20%3Cb%3ERifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E59%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.00388-2022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rifapentine%20access%20in%20Europe%3A%20growing%20concerns%20over%20key%20tuberculosis%20treatment%20component%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gunar%22%2C%22lastName%22%3A%22G%5Cu00fcnther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Leu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alberto%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateja%22%2C%22lastName%22%3A%22Jankovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florian%20P.%22%2C%22lastName%22%3A%22Maurer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20van%22%2C%22lastName%22%3A%22Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetLack%20of%20access%20to%20rifapentine%20in%20Europe%20denies%20patients%20optimal%20care%20for%20active%20tuberculosis%20and%20latent%20tuberculosis%20infection%2C%20and%20deprives%20healthcare%20providers%20of%20adequate%20tools%20to%20pursue%20tuberculosis%20control%20and%20elimination%20https%3A%5C%2F%5C%2Fbit.ly%5C%2F3jz85eh%22%2C%22date%22%3A%222022%5C%2F05%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.00388-2022%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F59%5C%2F5%5C%2F2200388%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-29T14%3A23%3A00Z%22%7D%7D%2C%7B%22key%22%3A%22MY9BQ8HY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guyeux%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuyeux%2C%20C.%2C%20Senelle%2C%20G.%2C%20Refr%26%23xE9%3Bgier%2C%20G.%2C%20Bretelle-Establet%2C%20F.%2C%20Cambau%2C%20E.%20and%20Sola%2C%20C.%20%282022%29.%20%3Cb%3EConnection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%3C%5C%2Fb%3E.%20Epidemiology%20%26amp%3B%20Infection%20%3Ci%3E150%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1017%5C%2FS0950268822000048%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Connection%20between%20two%20historical%20tuberculosis%20outbreak%20sites%20in%20Japan%2C%20Honshu%2C%20by%20a%20new%20ancestral%20Mycobacterium%20tuberculosis%20L2%20sublineage%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Guyeux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaetan%22%2C%22lastName%22%3A%22Senelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guislaine%22%2C%22lastName%22%3A%22Refr%5Cu00e9gier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Bretelle-Establet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Sola%22%7D%5D%2C%22abstractNote%22%3A%22By%20gathering%20680%20publicly%20available%20Sequence%20Read%20Archives%20from%20isolates%20of%20Mycobacterium%20tuberculosis%20complex%20%28MTBC%29%20including%20190%20belonging%20to%20the%20lineage%202%20Beijing%2C%20and%20using%20an%20in-house%20bioinformatical%20pipeline%2C%20the%20TB-Annotator%2C%20that%20analyses%20more%20than%2050%20000%20characters%2C%20we%20describe%20herein%20a%20new%20L2%20sublineage%20from%2020%20isolates%20found%20in%20the%20Tochigi%20province%2C%20%28Japan%29%2C%20that%20we%20designate%20as%20asia%20ancestral%205%20%28AAnc5%29.%20These%20isolates%20harbour%20a%20number%20of%20specific%20criteria%20%2842%20SNPs%29%20and%20their%20intra-cluster%20pairwise%20distance%20suggests%20historical%20and%20not%20epidemiological%20transmission.%20These%20isolates%20harbour%20a%20mutation%20in%20rpoC%2C%20and%20do%20not%20fulfil%2C%20any%20of%20the%20modern%20Beijing%20lineage%20criteria%2C%20nor%20any%20of%20the%20other%20ancestral%20Beijing%20lineages%20described%20so%20far.%20Asia%20ancestral%205%20isolates%20do%20not%20possess%20mutT2%2058%20and%20ogt%2012%20characteristics%20of%20modern%20Beijing%2C%20but%20possess%20ancestral%20Beijing%20SNPs%20characteristics.%20By%20looking%20into%20the%20literature%2C%20we%20found%20a%20reference%20isolate%20ID381%2C%20described%20in%20Kobe%20and%20Osaka%20belonging%20to%20the%20%5Cu2018G3%5Cu2019%20group%2C%20sharing%2036%20out%20of%20the%2042%20specific%20SNPs%20found%20in%20AAnc5.%20We%20also%20assessed%20the%20intermediate%20position%20of%20the%20asia%20ancestral%204%20%28AAnc4%29%20sublineage%20recently%20described%20in%20Thailand%20and%20propose%20an%20improved%20classification%20of%20the%20L2%20that%20now%20includes%20AAnc4%20and%20AAnc5.%20By%20increasing%20the%20recruitment%20into%20TB-Annotator%20to%20around%203000%20genomes%20%28including%20642%20belonging%20to%20L2%29%2C%20we%20confirmed%20our%20results%20and%20discovered%20additional%20historical%20ancestral%20L2%20branches%20that%20remain%20to%20be%20investigated%20in%20more%20detail.%20We%20also%20present%2C%20in%20addition%2C%20some%20anthropological%20and%20historical%20data%20from%20Chinese%20and%20Japan%20history%20of%20tuberculosis%2C%20as%20well%20as%20from%20Korea%2C%20that%20could%20support%20our%20results%20on%20L2%20evolution.%20This%20study%20shows%20that%20the%20reconstruction%20of%20the%20early%20history%20of%20tuberculosis%20in%20Asia%20is%20likely%20to%20reveal%20complex%20patterns%20since%20its%20emergence.%22%2C%22date%22%3A%222022%5C%2Fed%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1017%5C%2FS0950268822000048%22%2C%22ISSN%22%3A%220950-2688%2C%201469-4409%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.cambridge.org%5C%2Fcore%5C%2Fjournals%5C%2Fepidemiology-and-infection%5C%2Farticle%5C%2Fconnection-between-two-historical-tuberculosis-outbreak-sites-in-japan-honshu-by-a-new-ancestral-mycobacterium-tuberculosis-l2-sublineage%5C%2F79482A3DD638BB99618B2CCDAA4EBC56%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A03Z%22%7D%7D%2C%7B%22key%22%3A%22A2TD2VUD%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Holmgaard%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EHolmgaard%2C%20F.%20B.%2C%20Guglielmetti%2C%20L.%2C%20Lillebaek%2C%20T.%2C%20Andersen%2C%20%26%23xC5%3B.%20B.%2C%20Wejse%2C%20C.%20and%20Dahl%2C%20V.%20N.%20%282022%29.%20%3Cb%3EEfficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%3C%5C%2Fb%3E.%20Clin%20Infect%20Dis%20ciac876%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciac876%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Efficacy%20and%20tolerability%20of%20concomitant%20use%20of%20bedaquiline%20and%20delamanid%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3A%20a%20systematic%20review%20and%20meta-analysis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Freja%20Breth%22%2C%22lastName%22%3A%22Holmgaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Troels%22%2C%22lastName%22%3A%22Lillebaek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%5Cu00c5se%20Bengaard%22%2C%22lastName%22%3A%22Andersen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Wejse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Victor%20Naestholt%22%2C%22lastName%22%3A%22Dahl%22%7D%5D%2C%22abstractNote%22%3A%22The%20introduction%20of%20two%20novel%20drugs%2C%20bedaquiline%20and%20delamanid%2C%20has%20given%20hope%20for%20better%20and%20shorter%20treatments%20of%20drug-resistant%20tuberculosis.%20A%20systematic%20review%20was%20conducted%20to%20evaluate%20the%20efficacy%20and%20safety%20of%20concomitant%20bedaquiline%20and%20delamanid%20administration.%20Pooled%20estimates%20of%20WHO-defined%20favorable%20treatment%20outcome%20and%20significant%20QTc-interval%20prolongation%20%28QTc%20%5Cu2265500%5Cu2005ms%20or%20%5Cu226560%5Cu2005ms%20increase%20from%20baseline%29%20were%20calculated%20using%20a%20random%20effects%20model.%20Thirteen%20studies%20including%20a%20total%20of%201031%20individuals%20with%20multidrug-resistant%5C%2Frifampicin-resistant%20tuberculosis%20who%20received%20bedaquiline%20and%20delamanid%20were%20included.%20The%20pooled%20estimate%20of%20favorable%20treatment%20outcome%20was%2073.1%25%20%2895%25CI%3A%2064.3-81.8%29.%20Sputum%20culture%20conversion%20at%20six%20months%20ranged%20from%2061-95%25.%20Overall%2C%20the%20pooled%20proportion%20of%20QTc-prolongation%20was%207.8%25%20%2895%25CI%3A%204.1-11.6%29%20and%20few%20cardiac%20events%20were%20reported%20%280.8%25%2C%20n%5Cu2009%3D%5Cu20096%5C%2F798%29.%20Rates%20of%20sputum%20culture%20conversion%20and%20favorable%20treatment%20outcome%20were%20high%20in%20patients%20treated%20concomitantly%20with%20bedaquiline%20and%20delamanid%2C%20and%20the%20treatment%20seemed%20tolerable%20with%20low%20rates%20of%20clinically%20significant%20cardiac%20toxicity.%22%2C%22date%22%3A%222022-11-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciac876%22%2C%22ISSN%22%3A%221537-6591%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-03-10T14%3A59%3A47Z%22%7D%7D%2C%7B%22key%22%3A%224ND3DBVZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Khan%20and%20Guglielmetti%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKhan%2C%20U.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EEvidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20900%26%23x2013%3B901%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.22.0328%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Evidence%20and%20ethical%20considerations%20for%20the%20treatment%20of%20contacts%20exposed%20to%20drug-resistant%20TB%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22U.%22%2C%22lastName%22%3A%22Khan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.22.0328%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222023-04-26T13%3A17%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22YKWPDBTM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-09%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Rioux%2C%20C.%2C%20Yazdanpanah%2C%20Y.%2C%20M%26%23xE9%3Bcha%26%23xEF%3B%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Robert%2C%20J.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ERevised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%26%23x2013%3B2019%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201796%26%23x2013%3B1804%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2809.220458%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Revised%20Definitions%20of%20Tuberculosis%20Resistance%20and%20Treatment%20Outcomes%2C%20France%2C%202006%5Cu20132019%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yazdan%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22M%5Cu00e9cha%5Cu00ef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Definitions%20of%20resistance%20in%20multidrug-resistant%20tuberculosis%20%28MDR%20TB%29%20and%20extensively%20drug-resistant%20tuberculosis%20%28XDR%20TB%29%20have%20been%20updated.%20Pre%5Cu2013XDR%20TB%2C%20defined%20as%20MDR%20TB%20with%20additional%20resistance%20to%20fluoroquinolones%2C%20and%20XDR%20TB%2C%20with%20additional%20resistance%20to%20bedaquiline%20or%20linezolid%2C%20are%20frequently%20associated%20with%20treatment%20failure%20and%20toxicity.%20We%20retrospectively%20determined%20the%20effects%20of%20pre-XDR%5C%2FXDR%20TB%20resistance%20on%20outcomes%20and%20safety%20of%20MDR%20TB%20treatment%20in%20France.%20The%20study%20included%20298%20patients%20treated%20for%20MDR%20TB%20at%203%20reference%20centers%20during%202006%5Cu20132019.%20Of%20those%2C%20205%20%2868.8%25%29%20cases%20were%20fluoroquinolone-susceptible%20MDR%20TB%20and%2093%20%2831.2%25%29%20were%20pre-XDR%5C%2FXDR%20TB.%20Compared%20with%20fluoroquinolone-susceptible%20MDR%20TB%2C%20pre-XDR%5C%2FXDR%20TB%20was%20associated%20with%20more%20cavitary%20lung%20lesions%20and%20bilateral%20disease%20and%20required%20longer%20treatment.%20Overall%2C%20202%20patients%20%2867.8%25%29%20had%20favorable%20treatment%20outcomes%2C%20with%20no%20significant%20difference%20between%20pre-XDR%5C%2FXDR%20TB%20%2867.7%25%29%20and%20fluoroquinolone-susceptible%20MDR%20TB%20%2867.8%25%3B%20p%20%3D%200.99%29.%20Pre-XDR%5C%2FXDR%20TB%20was%20not%20associated%20with%20higher%20risk%20for%20serious%20adverse%20events.%22%2C%22date%22%3A%222022-9%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2809.220458%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9423894%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A14%3A59Z%22%7D%7D%2C%7B%22key%22%3A%22JXJYY2QR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kherabi%20et%20al.%22%2C%22parsedDate%22%3A%222022-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKherabi%2C%20Y.%2C%20Tunesi%2C%20S.%2C%20Kay%2C%20A.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3EPreventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Pathogens%20%3Ci%3E11%3C%5C%2Fi%3E%2C%201189%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fpathogens11101189%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Preventive%20Therapy%20for%20Contacts%20of%20Drug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yousra%22%2C%22lastName%22%3A%22Kherabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexander%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22Preventing%20the%20progression%20of%20a%20drug-resistant%20tuberculosis%20%28DR-TB%29%20infection%20to%20disease%20is%20an%20important%20pillar%20of%20the%20DR-TB%20elimination%20strategy.%20International%20guidelines%20have%20recently%20proposed%20fluoroquinolones%20for%20tuberculosis%20preventive%20therapy%20%28TPT%29%20in%20DR-TB%20contacts%2C%20although%20the%20available%20evidence%20is%20low%20quality.%20The%20pooled%20data%20from%20small%20observational%20studies%20suggest%20that%20a%20fluoroquinolone-based%20TPT%20is%20safe%2C%20effective%20and%20cost-effective%20as%20a%20preventive%20treatment%20in%20DR-TB%20contacts.%20Three%20clinical%20trials%20are%20currently%20ongoing%20to%20generate%20higher%20quality%20evidence%20on%20the%20efficacy%20of%20levofloxacin%20and%20delamanid%20as%20a%20DR-TB%20preventive%20therapy.%20Additional%20evidence%20is%20also%20needed%2C%20regarding%20TPT%20treatment%20in%20fluoroquinolone-resistant-TB%20contacts%2C%20patient%20and%20health%20care%20worker%20perceptions%20on%20DR-TB%20preventive%20therapy%20for%20contacts%2C%20and%20the%20service%20delivery%20models%20to%20increase%20DR-TPT%20access.%20This%20state-of-the-art%20review%20presents%20the%20current%20literature%20on%20TPT%20for%20contacts%20of%20DR-TB%20cases%2C%20focusing%20on%20the%20available%20evidence%20and%20international%20guidelines.%22%2C%22date%22%3A%222022%5C%2F10%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fpathogens11101189%22%2C%22ISSN%22%3A%222076-0817%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-0817%5C%2F11%5C%2F10%5C%2F1189%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A55Z%22%7D%7D%2C%7B%22key%22%3A%223SA6SQXF%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kilin%5Cu00e7%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-24%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKilin%26%23xE7%3B%2C%20G.%2C%20Walburg%2C%20K.%20V.%2C%20Franken%2C%20K.%20L.%20M.%20C.%2C%20Valkenburg%2C%20M.%20L.%2C%20Aubry%2C%20A.%2C%20Haks%2C%20M.%20C.%2C%20Saris%2C%20A.%20and%20Ottenhoff%2C%20T.%20H.%20M.%20%282022%29.%20%3Cb%3EDevelopment%20of%20Human%20Cell-Based%20In%20Vitro%20Infection%20Models%20to%20Determine%20the%20Intracellular%20Survival%20of%20Mycobacterium%20avium%3C%5C%2Fb%3E.%20Front%20Cell%20Infect%20Microbiol%20%3Ci%3E12%3C%5C%2Fi%3E%2C%20872361%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2022.872361%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffcimb.2022.872361%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Development%20of%20Human%20Cell-Based%20In%20Vitro%20Infection%20Models%20to%20Determine%20the%20Intracellular%20Survival%20of%20Mycobacterium%20avium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00fcl%22%2C%22lastName%22%3A%22Kilin%5Cu00e7%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kimberley%20V.%22%2C%22lastName%22%3A%22Walburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kees%20L.%20M.%20C.%22%2C%22lastName%22%3A%22Franken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Merel%20L.%22%2C%22lastName%22%3A%22Valkenburg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mari%5Cu00eblle%20C.%22%2C%22lastName%22%3A%22Haks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anno%22%2C%22lastName%22%3A%22Saris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tom%20H.%20M.%22%2C%22lastName%22%3A%22Ottenhoff%22%7D%5D%2C%22abstractNote%22%3A%22The%20Mycobacterium%20avium%20%28Mav%29%20complex%20accounts%20for%20more%20than%2080%25%20of%20all%20pulmonary%20diseases%20caused%20by%20non-tuberculous%20mycobacteria%20%28NTM%29%20infections%2C%20which%20have%20an%20alarming%20increase%20in%20prevalence%20and%20vary%20in%20different%20regions%2C%20currently%20reaching%200.3%5Cu20139.8%20per%20100%2C000%20individuals.%20Poor%20clinical%20outcomes%2C%20as%20a%20result%20of%20increasing%20microbial%20drug%20resistance%20and%20low%20treatment%20adherence%20due%20to%20drug-toxicities%2C%20emphasize%20the%20need%20for%20more%20effective%20treatments.%20Identification%20of%20more%20effective%20treatments%2C%20however%2C%20appears%20to%20be%20difficult%2C%20which%20may%20be%20due%20to%20the%20intracellular%20life%20of%20NTM%20and%20concomitant%20altered%20drug%20sensitivity%20that%20is%20not%20taken%20into%20account%20using%20traditional%20drug%20susceptibility%20testing%20screenings.%20We%20therefore%20developed%20human%20cell-based%20in%20vitro%20Mav%20infection%20models%20using%20the%20human%20MelJuSo%20cell%20line%20as%20well%20as%20primary%20human%20macrophages%20and%20a%20fluorescently%20labeled%20Mav%20strain.%20By%20testing%20a%20range%20of%20multiplicity%20of%20infection%20%28MOI%29%20and%20using%20flow%20cytometry%20and%20colony-forming%20unit%20%28CFU%29%20analysis%2C%20we%20found%20that%20an%20MOI%20of%2010%20was%20the%20most%20suitable%20for%20Mav%20infection%20in%20primary%20human%20macrophages%2C%20whereas%20an%20MOI%20of%2050%20was%20required%20to%20achieve%20similar%20results%20in%20MelJuSo%20cells.%20Moreover%2C%20by%20monitoring%20intracellular%20bacterial%20loads%20over%20time%2C%20the%20macrophages%20were%20shown%20to%20be%20capable%20of%20controlling%20the%20infection%2C%20while%20MelJuSo%20cells%20failed%20to%20do%20so.%20When%20comparing%20the%20MGIT%20system%20with%20the%20classical%20CFU%20counting%20assay%20to%20determine%20intracellular%20bacterial%20loads%2C%20MGIT%20appeared%20as%20a%20less%20labor-intensive%2C%20more%20precise%2C%20and%20more%20objective%20alternative.%20Next%2C%20using%20our%20macrophage%20Mav%20infection%20models%2C%20the%20drug%20efficacy%20of%20the%20first-line%20drug%20rifampicin%20and%20the%20more%20recently%20discovered%20bedaquiline%20on%20intracellular%20bacteria%20was%20compared%20to%20the%20activity%20on%20extracellular%20bacteria.%20The%20efficacy%20of%20the%20antibiotics%20inhibiting%20bacterial%20growth%20was%20significantly%20lower%20against%20intracellular%20bacteria%20compared%20to%20extracellular%20bacteria.%20This%20finding%20emphasizes%20the%20crucial%20role%20of%20the%20host%20cell%20during%20infection%20and%20drug%20susceptibility%20and%20highlights%20the%20usefulness%20of%20the%20models.%20Taken%20together%2C%20the%20human%20cell-based%20Mav%20infection%20models%20are%20reliable%20tools%20to%20determine%20the%20intracellular%20loads%20of%20Mav%2C%20which%20will%20enable%20researchers%20to%20investigate%20host%5Cu2013pathogen%20interactions%20and%20to%20evaluate%20the%20efficacy%20of%20%28host-directed%29%20therapeutic%20strategies%20against%20Mav.%22%2C%22date%22%3A%222022-6-24%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffcimb.2022.872361%22%2C%22ISSN%22%3A%222235-2988%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9263196%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A31%3A19Z%22%7D%7D%2C%7B%22key%22%3A%224KRX87K9%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kraef%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKraef%2C%20C.%2C%20Lindquist%2C%20E.%2C%20Svensson%2C%20E.%20and%20Cambau%2C%20E.%20%282022%29.%20%3Cb%3EDiagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%3C%5C%2Fb%3E%20Clinical%20Microbiology%20and%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.cmi.2022.06.022%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Diagnostic%20toolkit%20for%20tuberculosis%3A%20should%20we%20include%20urine%20lipoarabinomannan%20%28LAM%29%20detection%20in%20the%20WHO%20European%20Region%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Kraef%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilia%22%2C%22lastName%22%3A%22Lindquist%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22Svensson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-07-05%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.cmi.2022.06.022%22%2C%22ISSN%22%3A%221198-743X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1198743X22003366%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A28%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22WWYPJGM4%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lange%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELange%2C%20C.%2C%20B%26%23xF6%3Bttger%2C%20E.%20C.%2C%20Cambau%2C%20E.%2C%20Griffith%2C%20D.%20E.%2C%20Guglielmetti%2C%20L.%2C%20van%20Ingen%2C%20J.%2C%20Knight%2C%20S.%20L.%2C%20Marras%2C%20T.%20K.%2C%20Olivier%2C%20K.%20N.%2C%20Santin%2C%20M.%2C%20Stout%2C%20J.%20E.%2C%20Tortoli%2C%20E.%2C%20Wagner%2C%20D.%2C%20Winthrop%2C%20K.%2C%20Daley%2C%20C.%20L.%2C%20Lange%2C%20C.%2C%20Andrejak%2C%20C.%2C%20B%26%23xF6%3Bttger%2C%20E.%2C%20Cambau%2C%20E.%2C%20Griffith%2C%20D.%2C%20Guglielmetti%2C%20L.%2C%20van%20Ingen%2C%20J.%2C%20Knight%2C%20S.%2C%20Leitman%2C%20P.%2C%20Marras%2C%20T.%20K.%2C%20Olivier%2C%20K.%20N.%2C%20Santin%2C%20M.%2C%20Stout%2C%20J.%20E.%2C%20Tortoli%2C%20E.%2C%20Wagner%2C%20D.%2C%20Wallace%2C%20R.%20J.%2C%20Winthrop%2C%20K.%20and%20Daley%2C%20C.%20%282022%29.%20%3Cb%3EConsensus%20management%20recommendations%20for%20less%20common%20non-tuberculous%20mycobacterial%20pulmonary%20diseases%3C%5C%2Fb%3E.%20The%20Lancet%20Infectious%20Diseases%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2821%2900586-7%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS1473-3099%2821%2900586-7%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Consensus%20management%20recommendations%20for%20less%20common%20non-tuberculous%20mycobacterial%20pulmonary%20diseases%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%20C%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20E%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shandra%20L%22%2C%22lastName%22%3A%22Knight%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%20K%22%2C%22lastName%22%3A%22Marras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20N%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%20E%22%2C%22lastName%22%3A%22Stout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Tortoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Winthrop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20L%22%2C%22lastName%22%3A%22Daley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erik%22%2C%22lastName%22%3A%22B%5Cu00f6ttger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Griffith%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakko%22%2C%22lastName%22%3A%22van%20Ingen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shandra%22%2C%22lastName%22%3A%22Knight%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Leitman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Theodore%20K.%22%2C%22lastName%22%3A%22Marras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20N.%22%2C%22lastName%22%3A%22Olivier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Miguel%22%2C%22lastName%22%3A%22Santin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jason%20E.%22%2C%22lastName%22%3A%22Stout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Tortoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%22%2C%22lastName%22%3A%22Wagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20J.%22%2C%22lastName%22%3A%22Wallace%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Winthrop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%22%2C%22lastName%22%3A%22Daley%22%7D%5D%2C%22abstractNote%22%3A%22The%202020%20clinical%20practice%20guideline%20for%20the%20treatment%20of%20non-tuberculous%20mycobacterial%20pulmonary%20disease%20%28NTM-PD%29%20by%20the%20American%20Thoracic%20Society%2C%20European%20Respiratory%20Society%2C%20European%20Society%20of%20Clinical%20Microbiology%20and%20Infectious%20Diseases%2C%20and%20Infectious%20Diseases%20Society%20of%20America%3B%20and%20the%202017%20management%20guideline%20by%20the%20British%20Thoracic%20Society%20covered%20pulmonary%20diseases%20in%20adults%20caused%20by%20Mycobacterium%20avium%20complex%2C%20Mycobacterium%20kansasii%2C%20Mycobacterium%20xenopi%2C%20and%20Mycobacterium%20abscessus.%20In%20order%20to%20provide%20evidence-based%20recommendations%20for%20the%20treatment%20of%20less%20common%20non-tuberculous%20mycobacterial%20%28NTM%29%20species%20in%20adult%20patients%20without%20cystic%20fibrosis%20or%20HIV%20infection%2C%20our%20expert%20panel%20group%20performed%20systematic%20literature%20searches%20to%20provide%20management%20guidance%20for%20pulmonary%20diseases%20caused%20by%20seven%20additional%20organisms%3A%20Mycobacterium%20chelonae%2C%20Mycobacterium%20fortuitum%2C%20Mycobacterium%20genavense%2C%20Mycobacterium%20gordonae%2C%20Mycobacterium%20malmoense%2C%20Mycobacterium%20simiae%2C%20and%20Mycobacterium%20szulgai.%20Treatment%20recommendations%20were%20developed%20by%20a%20structured%20consensus%20process.%20The%20evidence%20from%20the%20scientific%20literature%20published%20in%20English%20for%20treatment%20recommendations%20for%20pulmonary%20diseases%20caused%20by%20other%20NTM%20species%20was%20of%20very%20low%20quality%2C%20with%20the%20exception%20of%20M%20malmoense%2C%20and%20based%20on%20the%20evaluation%20of%20case%20reports%20and%20case%20series.%20For%20M%20malmoense%2C%20results%20from%20two%20randomised%20controlled%20trials%20and%20three%20retrospective%20cohort%20studies%20provided%20a%20better%20evidence%20base%20for%20treatment%20recommendations%2C%20although%20the%20evidence%20was%20still%20of%20low%20quality.%22%2C%22date%22%3A%222022-01-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS1473-3099%2821%2900586-7%22%2C%22ISSN%22%3A%221473-3099%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS1473309921005867%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A15%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22DP27S3F7%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Le%20Ray%20et%20al.%22%2C%22parsedDate%22%3A%222022-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELe%20Ray%2C%20L.%20F.%2C%20Aubry%2C%20A.%2C%20Sougakoff%2C%20W.%2C%20Revest%2C%20M.%2C%20Robert%2C%20J.%2C%20Bonnet%2C%20I.%2C%20Veziris%2C%20N.%20and%20Morel%2C%20F.%20%282022%29.%20%3Cb%3EatpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E28%3C%5C%2Fi%3E%2C%201062%26%23x2013%3B1064%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2805.212517%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22atpE%20Mutation%20in%20Mycobacterium%20tuberculosis%20Not%20Always%20Predictive%20of%20Bedaquiline%20Treatment%20Failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%20Fournier%22%2C%22lastName%22%3A%22Le%20Ray%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Revest%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Bonnet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20the%20emergence%20of%20an%20atpE%20mutation%20in%20a%20clinical%20Mycobacterium%20tuberculosis%20strain.%20Genotypic%20and%20phenotypic%20bedaquiline%20susceptibility%20testing%20displayed%20variable%20results%20over%20time%20and%20ultimately%20were%20not%20predictive%20of%20treatment%20outcome.%20This%20observation%20highlights%20the%20limits%20of%20current%20genotypic%20and%20phenotypic%20methods%20for%20detection%20of%20bedaquiline%20resistance.%22%2C%22date%22%3A%222022-5%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2805.212517%22%2C%22ISSN%22%3A%221080-6040%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC9045433%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-07-06T13%3A29%3A33Z%22%7D%7D%2C%7B%22key%22%3A%22VG5PNGPC%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Maitre%20et%20al.%22%2C%22parsedDate%22%3A%222022-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMaitre%2C%20T.%2C%20Morel%2C%20F.%2C%20Brossier%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Jaffre%2C%20J.%2C%20Cheng%2C%20S.%2C%20Veziris%2C%20N.%2C%20Aubry%2C%20A.%20and%20on%20behalf%20of%20the%20NRC-MyRMA%20%282022%29.%20%3Cb%3EHow%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%3C%5C%2Fb%3E.%20Microorganisms%20%3Ci%3E10%3C%5C%2Fi%3E%2C%201436%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fmicroorganisms10071436%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22How%20a%20PCR%20Sequencing%20Strategy%20Can%20Bring%20New%20Data%20to%20Improve%20the%20Diagnosis%20of%20Ethionamide%20Resistance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Morel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9remy%22%2C%22lastName%22%3A%22Jaffre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sokleaph%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22on%20behalf%20of%20the%20NRC-MyRMA%22%7D%5D%2C%22abstractNote%22%3A%22Ethionamide%20%28ETH%29%20is%20a%20second-line%20antituberculosis%20drug.%20ETH%20resistance%20%28ETH-R%29%20is%20mainly%20related%20to%20the%20mutations%20of%20the%20monooxygenase-activating%20ETH%20%28EthA%29%2C%20the%20ETH%20target%20%28InhA%29%2C%20and%20the%20inhA%20promoter.%20Nonetheless%2C%20diagnosing%20ETH-R%20is%20still%20challenging.%20We%20assessed%20the%20strategy%20used%20for%20detecting%20ETH-R%20at%20the%20French%20National%20Reference%20Center%20for%20Mycobacteria%20in%20497%20MDR-TB%20isolates%20received%20from%202008%20to%202016.%20The%20genotypic%20ETH%5Cu2019s%20resistance%20detection%20was%20performed%20by%20sequencing%20ethA%2C%20ethR%2C%20the%20ethA-ethR%20intergenic%20region%2C%20and%20the%20inhA%20promoter%20in%20the%20497%20multidrug-resistant%20isolates%2C%20whereas%20the%20phenotypic%20ETH%20susceptibility%20testing%20%28PST%29%20was%20performed%20using%20the%20reference%20proportion%20method.%20Mutations%20were%20found%20in%20up%20to%2076%25%20of%20the%20387%20resistant%20isolates%20and%20in%20up%20to%2028%25%20of%20the%20110%20susceptible%20isolates.%20Our%20results%20do%20not%20support%20the%20role%20of%20ethR%20mutations%20in%20ETH%20resistance.%20Altogether%2C%20the%20positive%20predictive%20value%20of%20our%20genotypic%20strategy%20to%20diagnose%20ETH-R%20was%20improved%20when%20only%20considering%20the%20variants%20included%20in%20the%20WHO%20catalogue%20and%20in%20other%20databases%2C%20such%20as%20TB-Profiler.%20Therefore%2C%20our%20work%20will%20help%20to%20update%20the%20list%20of%20mutations%20that%20could%20be%20graded%20as%20being%20associated%20with%20resistance%20to%20improve%20ETH-R%20diagnosis.%22%2C%22date%22%3A%222022%5C%2F7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fmicroorganisms10071436%22%2C%22ISSN%22%3A%222076-2607%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2076-2607%5C%2F10%5C%2F7%5C%2F1436%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A18%3A47Z%22%7D%7D%2C%7B%22key%22%3A%222V395TDR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Marijke%20Braet%20et%20al.%22%2C%22parsedDate%22%3A%222022-09-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMarijke%20Braet%2C%20S.%2C%20Jouet%2C%20A.%2C%20Aubry%2C%20A.%2C%20Van%20Dyck-Lippens%2C%20M.%2C%20Lenoir%2C%20E.%2C%20Assoumani%2C%20Y.%2C%20Baco%2C%20A.%2C%20Mzembaba%2C%20A.%2C%20Cambau%2C%20E.%2C%20Vasconcellos%2C%20S.%20E.%20G.%2C%20Rigouts%2C%20L.%2C%20Suffys%2C%20P.%20N.%2C%20Hasker%2C%20E.%2C%20Supply%2C%20P.%20and%20de%20Jong%2C%20B.%20C.%20%282022%29.%20%3Cb%3EInvestigating%20drug%20resistance%20of%20Mycobacterium%20leprae%20in%20the%20Comoros%3A%20an%20observational%20deep-sequencing%20study%3C%5C%2Fb%3E.%20The%20Lancet%20Microbe%20%3Ci%3E3%3C%5C%2Fi%3E%2C%20e693%26%23x2013%3Be700%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2822%2900117-3%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2FS2666-5247%2822%2900117-3%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Investigating%20drug%20resistance%20of%20Mycobacterium%20leprae%20in%20the%20Comoros%3A%20an%20observational%20deep-sequencing%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sofie%22%2C%22lastName%22%3A%22Marijke%20Braet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agathe%22%2C%22lastName%22%3A%22Jouet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magalie%22%2C%22lastName%22%3A%22Van%20Dyck-Lippens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esteban%22%2C%22lastName%22%3A%22Lenoir%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Younoussa%22%2C%22lastName%22%3A%22Assoumani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdallah%22%2C%22lastName%22%3A%22Baco%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aboubacar%22%2C%22lastName%22%3A%22Mzembaba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sidra%20Ezidio%20Gon%5Cu00e7alves%22%2C%22lastName%22%3A%22Vasconcellos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leen%22%2C%22lastName%22%3A%22Rigouts%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%20Noel%22%2C%22lastName%22%3A%22Suffys%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Epco%22%2C%22lastName%22%3A%22Hasker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Supply%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bouke%20Catherine%22%2C%22lastName%22%3A%22de%20Jong%22%7D%5D%2C%22abstractNote%22%3A%22Background%5CnDespite%20strong%20leprosy%20control%20measures%2C%20including%20effective%20treatment%2C%20leprosy%20persists%20in%20the%20Comoros.%20As%20of%20May%2C%202022%2C%20no%20resistance%20to%20anti-leprosy%20drugs%20had%20been%20reported%2C%20but%20there%20are%20no%20nationally%20representative%20data.%20Post-exposure%20prophylaxis%20%28PEP%29%20with%20rifampicin%20is%20offered%20to%20contacts%20of%20patients%20with%20leprosy.%20We%20aimed%20to%20conduct%20a%20countrywide%20drug%20resistance%20survey%20and%20investigate%20whether%20PEP%20led%20to%20the%20emergence%20of%20drug%20resistance%20in%20patients%20with%20leprosy.%5CnMethods%5CnIn%20this%20observational%2C%20deep-sequencing%20analysis%20we%20assessed%20Mycobacterium%20leprae%20genomes%20from%20skin%20biopsies%20of%20patients%20in%20Anjouan%20and%20Moh%5Cu00e9li%2C%20Comoros%2C%20collected%20as%20part%20of%20the%20ComLep%20%28NCT03526718%29%20and%20PEOPLE%20%28NCT03662022%29%20studies.%20Skin%20biopsies%20that%20had%20sufficient%20M%20leprae%20DNA%20%28%3E2000%20bacilli%20in%202%20%5Cu03bcl%20of%20DNA%20extract%29%20were%20assessed%20for%20the%20presence%20of%20seven%20drug%20resistance-associated%20genes%20%28ie%2C%20rpoB%2C%20ctpC%2C%20ctpI%2C%20folP1%2C%20gyrA%2C%20gyrB%2C%20and%20nth%29%20using%20Deeplex%20Myc-Lep%20%28targeted%20next%20generation%20deep%20sequencing%29%2C%20with%20a%20limit%20of%20detection%20of%2010%25%20for%20minority%20M%20leprae%20bacterial%20populations%20bearing%20a%20polymorphism%20in%20these%20genes.%20All%20newly%20registered%20patients%20with%20leprosy%20for%20whom%20written%20informed%20consent%20was%20obtained%20were%20eligible%20for%20inclusion%20in%20the%20survey.%20Patients%20younger%20than%202%20years%20or%20with%20a%20single%20lesion%20on%20the%20face%20did%20not%20have%20biopsies%20taken.%20The%20primary%20outcome%20of%20our%20study%20was%20the%20proportion%20of%20patients%20with%20leprosy%20%28ie%2C%20new%20cases%2C%20patients%20with%20relapses%20or%20reinfections%2C%20patients%20who%20received%20single%20%28double%29%20dose%20rifampicin-PEP%2C%20or%20patients%20who%20lived%20in%20villages%20where%20PEP%20was%20distributed%29%20who%20were%20infected%20with%20M%20leprae%20with%20a%20drug-resistant%20mutation%20for%20rifampicin%2C%20fluoroquinolone%2C%20or%20dapsone%20in%20the%20Comoros.%5CnFindings%5CnBetween%20July%201%2C%202017%2C%20and%20Dec%2031%2C%202020%2C%201199%20patients%20with%20leprosy%20were%20identified%20on%20the%20basis%20of%20clinical%20criteria%2C%20of%20whom%201030%20provided%20a%20skin%20biopsy.%20Of%20these%201030%20patients%2C%20755%20%2873%5Cu00b73%25%29%20tested%20positive%20for%20the%20M%20leprae-specific%20repetitive%20element-quantitative%20PCR%20%28qPCR%29%20assay.%20Of%20these%20755%20patients%2C%20260%20%2834%5Cu00b74%25%29%20were%20eligible%20to%20be%20analysed%20using%20Deeplex%20Myc-Lep.%20251%20%2896%5Cu00b75%25%29%20were%20newly%20diagnosed%20with%20leprosy%2C%20whereas%20nine%20%283%5Cu00b74%25%29%20patients%20had%20previously%20received%20multidrug%20therapy.%2045%20%2817%5Cu00b73%25%29%20patients%20resided%20in%20villages%20where%20PEP%20had%20been%20administered%20in%202015%20or%202019%2C%20two%20%284%5Cu00b74%25%29%20of%20whom%20received%20PEP.%20All%20seven%20drug%20resistance-associated%20targets%20were%20successfully%20sequenced%20in%20216%20samples%2C%2039%20samples%20had%20incomplete%20results%2C%20and%20five%20had%20no%20results.%20No%20mutations%20were%20detected%20in%20any%20of%20the%20seven%20drug%20resistance-related%20genes%20for%20any%20patient%20with%20successfully%20sequenced%20results.%5CnInterpretation%5CnThis%20drug%20resistance%20survey%20provides%20evidence%20to%20show%20that%20M%20leprae%20is%20fully%20susceptible%20to%20rifampicin%2C%20fluoroquinolones%2C%20and%20dapsone%20in%20the%20Comoros.%20Our%20results%20also%20show%2C%20for%20the%20first%20time%2C%20the%20applicability%20of%20targeted%20sequencing%20directly%20on%20skin%20biopsies%20from%20patients%20with%20either%20paucibacillary%20or%20multibacillary%20leprosy.%20These%20data%20suggest%20that%20PEP%20had%20not%20selected%20rifampicin-resistant%20strains%2C%20although%20further%20support%20for%20this%20finding%20should%20be%20confirmed%20with%20a%20larger%20sample%20size.%5CnFunding%5CnEffect%3AHope%2C%20The%20Mission%20To%20End%20Leprosy%2C%20the%20Fonds%20Wetenschappelijk%20Onderzoek%2C%20the%20EU.%22%2C%22date%22%3A%222022-09-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2FS2666-5247%2822%2900117-3%22%2C%22ISSN%22%3A%222666-5247%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2666524722001173%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-09-23T13%3A29%3A27Z%22%7D%7D%2C%7B%22key%22%3A%22M3NEXJYZ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Migliori%20et%20al.%22%2C%22parsedDate%22%3A%222022-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMigliori%2C%20G.%20B.%2C%20Wu%2C%20S.%20J.%2C%20Matteelli%2C%20A.%2C%20Zenner%2C%20D.%2C%20Goletti%2C%20D.%2C%20Ahmedov%2C%20S.%2C%20Al-Abri%2C%20S.%2C%20Allen%2C%20D.%20M.%2C%20Balcells%2C%20M.%20E.%2C%20Garcia-Basteiro%2C%20A.%20L.%2C%20Cambau%2C%20E.%2C%20Chaisson%2C%20R.%20E.%2C%20Chee%2C%20C.%20B.%20E.%2C%20Dalcolmo%2C%20M.%20P.%2C%20Denholm%2C%20J.%20T.%2C%20Erkens%2C%20C.%2C%20Esposito%2C%20S.%2C%20Farnia%2C%20P.%2C%20Friedland%2C%20J.%20S.%2C%20Graham%2C%20S.%2C%20Hamada%2C%20Y.%2C%20Harries%2C%20A.%20D.%2C%20Kay%2C%20A.%20W.%2C%20Kritski%2C%20A.%2C%20Manga%2C%20S.%2C%20Marais%2C%20B.%20J.%2C%20Menzies%2C%20D.%2C%20Ng%2C%20D.%2C%20Petrone%2C%20L.%2C%20Rendon%2C%20A.%2C%20Silva%2C%20D.%20R.%2C%20Schaaf%2C%20H.%20S.%2C%20Skrahina%2C%20A.%2C%20Sotgiu%2C%20G.%2C%20Thwaites%2C%20G.%2C%20Tiberi%2C%20S.%2C%20Tukvadze%2C%20N.%2C%20Zellweger%2C%20J.-P.%2C%20D%26%23x2019%3BAmbrosio%2C%20L.%2C%20Centis%2C%20R.%20and%20Ong%2C%20C.%20W.%20M.%20%282022%29.%20%3Cb%3EClinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E26%3C%5C%2Fi%3E%2C%20190%26%23x2013%3B205%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.21.0753%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Clinical%20standards%20for%20the%20diagnosis%2C%20treatment%20and%20prevention%20of%20TB%20infection%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%20B.%22%2C%22lastName%22%3A%22Migliori%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%20J.%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Matteelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Zenner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Ahmedov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Al-Abri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20M.%22%2C%22lastName%22%3A%22Allen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20E.%22%2C%22lastName%22%3A%22Balcells%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20L.%22%2C%22lastName%22%3A%22Garcia-Basteiro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%20E.%22%2C%22lastName%22%3A%22Chaisson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20B.%20E.%22%2C%22lastName%22%3A%22Chee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22Dalcolmo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20T.%22%2C%22lastName%22%3A%22Denholm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Erkens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Esposito%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Farnia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20S.%22%2C%22lastName%22%3A%22Friedland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Graham%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Hamada%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20D.%22%2C%22lastName%22%3A%22Harries%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%20W.%22%2C%22lastName%22%3A%22Kay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Kritski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Manga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%20J.%22%2C%22lastName%22%3A%22Marais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Menzies%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Ng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Petrone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Rendon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%20R.%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20S.%22%2C%22lastName%22%3A%22Schaaf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Sotgiu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thwaites%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Tukvadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.-P.%22%2C%22lastName%22%3A%22Zellweger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22D%5Cu2019Ambrosio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R.%22%2C%22lastName%22%3A%22Centis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20W.%20M.%22%2C%22lastName%22%3A%22Ong%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%5CnTuberculosis%20%28TB%29%20preventive%20therapy%20%28TPT%29%20decreases%20the%20risk%20of%20developing%20TB%20disease%20and%20its%20associated%20morbidity%20and%20mortality.%20The%20aim%20of%20these%20clinical%20standards%20is%20to%20guide%20the%20assessment%2C%20management%20of%20TB%20infection%20%28TBI%29%20and%20implementation%20of%20TPT.%5Cn%5CnMETHODS%3A%5CnA%20panel%20of%20global%20experts%20in%20the%20field%20of%20TB%20care%20was%20identified%3B%2041%20participated%20in%20a%20Delphi%20process.%20A%205-point%20Likert%20scale%20was%20used%20to%20score%20the%20initial%20standards.%20After%20rounds%20of%20revision%2C%20the%20document%20was%20approved%20with%20100%25%20agreement.%5Cn%5CnRESULTS%3A%5CnEight%20clinical%20standards%20were%20defined%3A%20Standard%201%2C%20all%20individuals%20belonging%20to%20at-risk%20groups%20for%20TB%20should%20undergo%20testing%20for%20TBI%3B%20Standard%202%2C%20all%20individual%20candidates%20for%20TPT%20%28including%20caregivers%20of%20children%29%20should%20undergo%20a%20counselling%5C%2Fhealth%20education%20session%3B%20Standard%203%2C%20testing%20for%20TBI%3A%20timing%20and%20test%20of%20choice%20should%20be%20optimised%3B%20Standard%204%2C%20TB%20disease%20should%20be%20excluded%20prior%20to%20initiation%20of%20TPT%3B%20Standard%205%2C%20all%20candidates%20for%20TPT%20should%20undergo%20a%20set%20of%20baseline%20examinations%3B%20Standard%206%2C%20all%20individuals%20initiating%20TPT%20should%20receive%20one%20of%20the%20recommended%20regimens%3B%20Standard%207%2C%20all%20individuals%20who%20have%20started%20TPT%20should%20be%20monitored%3B%20Standard%208%2C%20a%20TBI%20screening%20and%20testing%20register%20should%20be%20kept%20to%20inform%20the%20cascade%20of%20care.%5Cn%5CnCONCLUSION%3A%5CnThis%20is%20the%20first%20consensus-based%20set%20of%20Clinical%20Standards%20for%20TBI.%20This%20document%20guides%20clinicians%2C%20programme%20managers%20and%20public%20health%20officers%20in%20planning%20and%20implementing%20adequate%20measures%20to%20assess%20and%20manage%20TBI.%22%2C%22date%22%3A%222022-3%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.21.0753%22%2C%22ISSN%22%3A%221027-3719%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.ncbi.nlm.nih.gov%5C%2Fpmc%5C%2Farticles%5C%2FPMC8886963%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-05-26T21%3A18%3A54Z%22%7D%7D%2C%7B%22key%22%3A%22EDWVUW7S%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tunesi%20et%20al.%22%2C%22parsedDate%22%3A%222022-03-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETunesi%2C%20S.%2C%20D%26%23xFB%3B%2C%20D.%20L.%2C%20Gualano%2C%20G.%2C%20Millet%2C%20J.-P.%2C%20Skrahin%2C%20A.%2C%20Bothamley%2C%20G.%2C%20Casas%2C%20X.%2C%20Goletti%2C%20D.%2C%20Lange%2C%20C.%2C%20Musso%2C%20M.%2C%20Palmieri%2C%20F.%2C%20Pourcher%2C%20V.%2C%20Rioux%2C%20C.%2C%20Skrahina%2C%20A.%2C%20Veziris%2C%20N.%2C%20Viatushka%2C%20D.%2C%20Jachym-Fr%26%23xE9%3Bchet%2C%20M.%20and%20Guglielmetti%2C%20L.%20%282022%29.%20%3Cb%3ECo-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%3C%5C%2Fb%3E.%20Journal%20of%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jinf.2022.03.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Co-administration%20of%20treatment%20for%20rifampicin-resistant%20TB%20and%20chronic%20HCV%20infection%3A%20a%20TBnet%20and%20ESGMYC%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simone%22%2C%22lastName%22%3A%22Tunesi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%20Le%22%2C%22lastName%22%3A%22D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Gualano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joan-Pau%22%2C%22lastName%22%3A%22Millet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aliaksandr%22%2C%22lastName%22%3A%22Skrahin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Bothamley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Casas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delia%22%2C%22lastName%22%3A%22Goletti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Musso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizio%22%2C%22lastName%22%3A%22Palmieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dzmitry%22%2C%22lastName%22%3A%22Viatushka%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Jachym-Fr%5Cu00e9chet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-03-07%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jinf.2022.03.004%22%2C%22ISSN%22%3A%220163-4453%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS016344532200130X%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-16T14%3A21%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22JTCH47MP%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vongthilath-Moeung%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVongthilath-Moeung%2C%20R.%2C%20Plojoux%2C%20J.%2C%20Poncet%2C%20A.%2C%20Renzi%2C%20G.%2C%20Veziris%2C%20N.%2C%20Schrenzel%2C%20J.%20and%20Janssens%2C%20J.-P.%20%282022%29.%20%3Cb%3ENontuberculous%20Mycobacteria%20under%20Scrutiny%20in%20the%20Geneva%20Area%20%282015%26%23x2013%3B2020%29%3C%5C%2Fb%3E.%20RES%20%3Ci%3E101%3C%5C%2Fi%3E%2C%20367%26%23x2013%3B375%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000520033%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1159%5C%2F000520033%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Nontuberculous%20Mycobacteria%20under%20Scrutiny%20in%20the%20Geneva%20Area%20%282015%5Cu20132020%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rechana%22%2C%22lastName%22%3A%22Vongthilath-Moeung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Plojoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Poncet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gesuele%22%2C%22lastName%22%3A%22Renzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Schrenzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Paul%22%2C%22lastName%22%3A%22Janssens%22%7D%5D%2C%22abstractNote%22%3A%22%3Cb%3E%3Ci%3EBackground%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Nontuberculous%20mycobacteria%20%28NTM%29%20are%20increasingly%20identified%20in%20industrialized%20countries%2C%20and%20their%20role%20as%20pathogens%20is%20more%20frequently%20recognized.%20The%20relative%20prevalence%20of%20NTM%20strains%20shows%20an%20important%20geographical%20variability.%20Thus%2C%20establishing%20the%20local%20relative%20prevalence%20of%20NTM%20strains%20is%20relevant%20and%20useful%20for%20clinicians.%20%3Cb%3E%3Ci%3EMethods%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Retrospective%20analysis%20%282015%5Cu20132020%29%20of%20a%20comprehensive%20database%20was%20conducted%20including%20all%20results%20of%20cultures%20for%20mycobacteria%20in%20a%20University%20Hospital%20%28Geneva%2C%20Switzerland%29%2C%20covering%20a%20population%20of%20approximately%20500%2C000%20inhabitants.%20All%20NTM%20culture-positive%20patients%20were%20included%20in%20the%20analyses.%20Patients%5Cu2019%20characteristics%2C%20NTM%20strains%2C%20and%20time%20to%20culture%20positivity%20were%20reported.%20%3Cb%3E%3Ci%3EResults%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20Among%2038%2C065%20samples%20analyzed%20during%20the%20study%20period%2C%20411%20were%20culture-positive%20for%20NTM%2C%20representing%20236%20strains%2C%20and%20231%20episodes%20of%20care%20which%20occurred%20in%20222%20patients.%20Patients%20in%20whom%20NTM%20were%20identified%20were%20predominantly%20female%20%2855%25%29%2C%20with%20a%20median%20age%20of%2062%20years%2C%20and%20a%20low%20BMI%20%28median%3A%2022.6%20kg%5C%2Fm%3Csup%3E2%3C%5C%2Fsup%3E%29.%20The%20%3Ci%3EMycobacterium%20avium%3C%5C%2Fi%3E%20complex%20%28MAC%29%20was%20the%20most%20frequently%20identified%20group%20%2837%25%20of%20strains%29%20followed%20by%20%3Ci%3EMycobacterium%20gordonae%3C%5C%2Fi%3E%20%2825%25%29%20and%20%3Ci%3EMycobacterium%20xenopi%3C%5C%2Fi%3E%20%2812%25%29%20among%20the%20slowly%20growing%20mycobacteria%20%28SGM%29%2C%20while%20the%20%3Ci%3EMycobacterium%20chelonae%5C%2Fabscessus%3C%5C%2Fi%3E%20group%20%2811%25%29%20were%20the%20most%20frequently%20identified%20rapidly%20growing%20mycobacteria%20%28RGM%29.%20Only%2019%25%20of%20all%20patients%20were%20treated%2C%20mostly%20for%20pulmonary%20infections%3A%20the%20MAC%20was%20the%20most%20frequently%20treated%20NTM%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%2019%2C%2043%25%20of%20cases%20in%20patients%20treated%29%20followed%20by%20RGM%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%2015%2C%2034%25%29%20and%20%3Ci%3EM.%20xenopi%3C%5C%2Fi%3E%20%28%3Ci%3En%3C%5C%2Fi%3E%20%3D%206%2C%2014%25%29.%20Among%20those%20treated%2C%2023%25%20were%20immunosuppressed%2C%2012%25%20had%20pulmonary%20comorbidities%2C%20and%205%25%20systemic%20comorbidities.%20Cultures%20became%20positive%20after%20a%20median%20of%2041%20days%20%28IQR%3A%2023%3B%2068%29%20for%20SGM%20and%2028%20days%20%2814%3B%2035%29%20for%20RGM.%20%3Cb%3E%3Ci%3EConclusions%3A%3C%5C%2Fi%3E%3C%5C%2Fb%3E%20In%20Western%20Switzerland%2C%20%3Ci%3EM.%20avium%3C%5C%2Fi%3E%20and%20%3Ci%3EM.%20gordonae%3C%5C%2Fi%3E%20were%20the%20most%20prevalent%20NTM%20identified.%20Positive%20cultures%20for%20NTM%20led%20to%20a%20specific%20treatment%20in%2019%25%20of%20subjects.%20Patients%20with%20a%20positive%20culture%20for%20NTM%20were%20mostly%20female%2C%20with%20a%20median%20age%20of%2062%20years%2C%20a%20low%20BMI%2C%20and%20a%20low%20prevalence%20of%20immunosuppression%20or%20associated%20severe%20comorbidities.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22english%22%2C%22DOI%22%3A%2210.1159%5C%2F000520033%22%2C%22ISSN%22%3A%220025-7931%2C%201423-0356%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.karger.com%5C%2FArticle%5C%2FFullText%5C%2F520033%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T21%3A33%3A36Z%22%7D%7D%2C%7B%22key%22%3A%228NJBYM8Z%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Wetzstein%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EWetzstein%2C%20N.%2C%20Drummer%2C%20A.-P.%2C%20Bockey%2C%20A.%2C%20Herrmann%2C%20E.%2C%20K%26%23xFC%3Bpper-Tetzel%2C%20C.%20P.%2C%20Graf%2C%20C.%2C%20Koch%2C%20B.%2C%20Goetsch%2C%20U.%2C%20Vehreschild%2C%20M.%20J.%20G.%20T.%2C%20Guglielmetti%2C%20L.%2C%20Lange%2C%20B.%2C%20Wichelhaus%2C%20T.%20A.%20and%20Stephan%2C%20C.%20%282022%29.%20%3Cb%3EOccurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%26%23x2013%3B2018%3C%5C%2Fb%3E.%20Infection%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Occurrence%20of%20extrapulmonary%20tuberculosis%20is%20associated%20with%20geographical%20origin%3A%20spatial%20characteristics%20of%20the%20Frankfurt%20TB%20cohort%202013%5Cu20132018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Wetzstein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena-Pauline%22%2C%22lastName%22%3A%22Drummer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Annabelle%22%2C%22lastName%22%3A%22Bockey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eva%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%20Philippe%22%2C%22lastName%22%3A%22K%5Cu00fcpper-Tetzel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christiana%22%2C%22lastName%22%3A%22Graf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Koch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Udo%22%2C%22lastName%22%3A%22Goetsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20J.%20G.%20T.%22%2C%22lastName%22%3A%22Vehreschild%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20A.%22%2C%22lastName%22%3A%22Wichelhaus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Stephan%22%7D%5D%2C%22abstractNote%22%3A%22Tuberculosis%20%28TB%29%20is%20caused%20by%20M.%20tuberculosis%20complex%20%28MTB%29%20and%20pulmonary%20tuberculosis%20%28PTB%29%20is%20its%20classical%20manifestation.%20However%2C%20in%20some%20regions%20of%20the%20world%2C%20extrapulmonary%20TB%20%28EPTB%29%20seems%20to%20be%20more%20frequent.%22%2C%22date%22%3A%222022-10-01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs15010-022-01921-9%22%2C%22ISSN%22%3A%221439-0973%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs15010-022-01921-9%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-12-28T16%3A07%3A36Z%22%7D%7D%5D%7D
Aubry, A., Sammarco Rosa, P., Chauffour, A., Fletcher, M. L., Cambau, E. and Avanzi, C. (2022). Drug resistance in leprosy: An update following 70years of chemotherapy. Infectious Diseases Now 52, 243–251, http://doi.org/10.1016/j.idnow.2022.04.001.
Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, T., Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N. and Robert, J. (2022). Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. Journal of Infection 85, 24–30, http://doi.org/10.1016/j.jinf.2022.05.017.
Bonnet, I., Haddad, E., Guglielmetti, L., Bémer, P., Bernard, L., Bourgoin, A., Brault, R., Catho, G., Caumes, E., Escaut, L., Fourniols, E., Fréchet-Jachym, M., Gaudart, A., Guillot, H., Lafon-Desmurs, B., Lanoix, J.-P., Lanotte, P., Lemaignen, A., Lemaire, B., Lemaitre, N., Michau, C., Morand, P., Mougari, F., Marigot-Outtandy, D., Patrat-Delon, S., Perpoint, T., Piau, C., Pourcher, V., Zarrouk, V., Zeller, V., Veziris, N., Jauréguiberry, S. and Aubry, A. (2022). Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France. Microorganisms 10, 1215, http://doi.org/10.3390/microorganisms10061215.
Chaptal, M., Andrejak, C., Bonifay, T., Beillard, E., Guillot, G., Guyomard-Rabenirina, S., Demar, M., Trombert-Paolantoni, S., Jacomo, V., Mosnier, E., Veziris, N., Djossou, F., Epelboin, L. and Group, F. G. P. working (2022). Epidemiology of infection by pulmonary non-tuberculous mycobacteria in French Guiana 2008–2018. PLOS Neglected Tropical Diseases 16, e0010693, http://doi.org/10.1371/journal.pntd.0010693.
Chiron, R., Hoefsloot, W., Van Ingen, J., Marchandin, H., Kremer, L., Morisse-Pradier, H., Charriot, J., Mallet, J.-P., Herrmann, J.-L., Caimmi, D., Moreau, J., Dumont, Y., Godreuil, S., Bergeron, A., Drevait, M., Bouzat-Rossigneux, E., Terrail, N., Andrejak, C., Veziris, N., Grenet, D., Coudrat, A. and Catherinot, E. (2022). Amikacin Liposomal Inhalation Suspension in the Treatment of Mycobacterium abscessus Lung Infection: A French Observational Experience. Open Forum Infect Dis 9, ofac465, http://doi.org/10.1093/ofid/ofac465.
Daniau, C., Lecorche, E., Mougari, F., Benmansour, H., Bernet, C., Blanchard, H., Robert, J., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020. Emerg Infect Dis 28, 518–526, http://doi.org/10.3201/eid2803.211791.
Daniau, C., Berger-Carbonne, A. and Cambau, E. (2022). Association of Healthcare and Aesthetic Procedures with Infections Caused by Nontuberculous Mycobacteria, France, 2012‒2020 (response). Emerg Infect Dis 28, 1303–1304, http://doi.org/10.3201/eid2806.220686.
De Castro, N., Mechaï, F., Bachelet, D., Canestri, A., Joly, V., Vandenhende, M., Boutoille, D., Kerjouan, M., Veziris, N., Molina, J. M., Grall, N., Tattevin, P., Laouénan, C., Yazdanpanah, Y. and for the FAST TB Study Group (2022). Treatment With a Three-Drug Regimen for Pulmonary Tuberculosis Based on Rapid Molecular Detection of Isoniazid Resistance: A Noninferiority Randomized Trial (FAST-TB). Open Forum Infectious Diseases 9, ofac353, http://doi.org/10.1093/ofid/ofac353.
Eimer, J., Fréchet-Jachym, M., Le Dû, D., Caumes, E., El-Helali, N., Marigot-Outtandy, D., Mechai, F., Peytavin, G., Pourcher, V., Rioux, C., Yazdanpanah, Y., Robert, J., Guglielmetti, L. and for the LZDM group (2022). Increased linezolid plasma concentrations are associated with the development of severe toxicity in MDR-TB treatment. Clinical Infectious Diseases ciac485, http://doi.org/10.1093/cid/ciac485.
Group, A. S. T., Georghiou, S. B., Rodwell, T. C., Korobitsyn, A., Abbadi, S. H., Ajbani, K., Alffenaar, J.-W., Alland, D., Alvarez, N., Andres, S., Ardizzoni, E., Aubry, A., Baldan, R., Ballif, M., Barilar, I., Böttger, E. C., Chakravorty, S., Claxton, P. M., Cirillo, D. M., Comas, I., Coulter, C., Denkinger, C. M., Derendinger, B., Desmond, E. P., Steenwinkel, J. E. M. de, Dheda, K., Diacon, A. H., Dolinger, D. L., Dooley, K. E., Egger, M., Ehsani, S., Farhat, M. R., Fattorini, L., Finci, I., Ray, L. F. L., Furió, V., Groenheit, R., Gumbo, T., Heysell, S. K., Hillemann, D., Hoffmann, H., Hsueh, P.-R., Hu, Y., Huang, H., Hussain, A., Ismail, F., Izumi, K., Jagielski, T., Johnson, J. L., Kambli, P., Kaniga, K., Karunaratne, G. H. R. E., Sharma, M. K., Keller, P. M., Kelly, E. C., Kholina, M., Kohli, M., Kranzer, K., Laurenson, I. F., Limberis, J., Lin, S.-Y. G., Liu, Y., López-Gavín, A., Lyander, A., Machado, D., Martinez, E., Masood, F., Mitarai, S., Mvelase, N. R., Niemann, S., Nikolayevskyy, V., Maurer, F. P., Merker, M., Miotto, P., Omar, S. V., Otto-Knapp, R., Palaci, M., Gutiérrez, J. J. P., Peacock, S. J., Peloquin, C. A., Perera, J., Pierre-Audigier, C., Pholwat, S., Posey, J. E., Prammananan, T., Rigouts, L., Robledo, J., Rockwood, N., Rodrigues, C., Salfinger, M., Schechter, M. C., Seifert, M., Sengstake, S., Shinnick, T., Shubladze, N., Sintchenko, V., Sirgel, F., Somasundaram, S., Sterling, T. R., Spitaleri, A., Streicher, E., Supply, P., Svensson, E., Tagliani, E., Tahseen, S., Takaki, A., Theron, G., Torrea, G., Deun, A. V., Ingen, J. van, Rie, A. V., Soolingen, D. van, Jr, R. V., Venter, A., Veziris, N., Villellas, C., Viveiros, M., Warren, R., Wen, S., Werngren, J., Wilkinson, R. J., Yang, C., Yılmaz, F. F., Zhang, T., Zimenkov, D., Ismail, N., Köser, C. U. and Schön, T. (2022). Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00166-2022.
Guglielmetti, L., Günther, G., Leu, C., Cirillo, D., Duarte, R., Garcia-Basteiro, A. L., Goletti, D., Jankovic, M., Kuksa, L., Maurer, F. P., Méchaï, F., Tiberi, S., Leth, F. van, Veziris, N. and Lange, C. (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European Respiratory Journal 59, http://doi.org/10.1183/13993003.00388-2022.
Guyeux, C., Senelle, G., Refrégier, G., Bretelle-Establet, F., Cambau, E. and Sola, C. (2022). Connection between two historical tuberculosis outbreak sites in Japan, Honshu, by a new ancestral Mycobacterium tuberculosis L2 sublineage. Epidemiology & Infection 150, http://doi.org/10.1017/S0950268822000048.
Holmgaard, F. B., Guglielmetti, L., Lillebaek, T., Andersen, Å. B., Wejse, C. and Dahl, V. N. (2022). Efficacy and tolerability of concomitant use of bedaquiline and delamanid for multidrug- and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Clin Infect Dis ciac876, http://doi.org/10.1093/cid/ciac876.
Khan, U. and Guglielmetti, L. (2022). Evidence and ethical considerations for the treatment of contacts exposed to drug-resistant TB. The International Journal of Tuberculosis and Lung Disease 26, 900–901, http://doi.org/10.5588/ijtld.22.0328.
Kherabi, Y., Fréchet-Jachym, M., Rioux, C., Yazdanpanah, Y., Méchaï, F., Pourcher, V., Robert, J. and Guglielmetti, L. (2022). Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006–2019. Emerg Infect Dis 28, 1796–1804, http://doi.org/10.3201/eid2809.220458.
Kherabi, Y., Tunesi, S., Kay, A. and Guglielmetti, L. (2022). Preventive Therapy for Contacts of Drug-Resistant Tuberculosis. Pathogens 11, 1189, http://doi.org/10.3390/pathogens11101189.
Kilinç, G., Walburg, K. V., Franken, K. L. M. C., Valkenburg, M. L., Aubry, A., Haks, M. C., Saris, A. and Ottenhoff, T. H. M. (2022). Development of Human Cell-Based In Vitro Infection Models to Determine the Intracellular Survival of Mycobacterium avium. Front Cell Infect Microbiol 12, 872361, http://doi.org/10.3389/fcimb.2022.872361.
Kraef, C., Lindquist, E., Svensson, E. and Cambau, E. (2022). Diagnostic toolkit for tuberculosis: should we include urine lipoarabinomannan (LAM) detection in the WHO European Region? Clinical Microbiology and Infection, http://doi.org/10.1016/j.cmi.2022.06.022.
Lange, C., Böttger, E. C., Cambau, E., Griffith, D. E., Guglielmetti, L., van Ingen, J., Knight, S. L., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Winthrop, K., Daley, C. L., Lange, C., Andrejak, C., Böttger, E., Cambau, E., Griffith, D., Guglielmetti, L., van Ingen, J., Knight, S., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., Wagner, D., Wallace, R. J., Winthrop, K. and Daley, C. (2022). Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases. The Lancet Infectious Diseases, http://doi.org/10.1016/S1473-3099(21)00586-7.
Le Ray, L. F., Aubry, A., Sougakoff, W., Revest, M., Robert, J., Bonnet, I., Veziris, N. and Morel, F. (2022). atpE Mutation in Mycobacterium tuberculosis Not Always Predictive of Bedaquiline Treatment Failure. Emerg Infect Dis 28, 1062–1064, http://doi.org/10.3201/eid2805.212517.
Maitre, T., Morel, F., Brossier, F., Sougakoff, W., Jaffre, J., Cheng, S., Veziris, N., Aubry, A. and on behalf of the NRC-MyRMA (2022). How a PCR Sequencing Strategy Can Bring New Data to Improve the Diagnosis of Ethionamide Resistance. Microorganisms 10, 1436, http://doi.org/10.3390/microorganisms10071436.
Marijke Braet, S., Jouet, A., Aubry, A., Van Dyck-Lippens, M., Lenoir, E., Assoumani, Y., Baco, A., Mzembaba, A., Cambau, E., Vasconcellos, S. E. G., Rigouts, L., Suffys, P. N., Hasker, E., Supply, P. and de Jong, B. C. (2022). Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. The Lancet Microbe 3, e693–e700, http://doi.org/10.1016/S2666-5247(22)00117-3.
Migliori, G. B., Wu, S. J., Matteelli, A., Zenner, D., Goletti, D., Ahmedov, S., Al-Abri, S., Allen, D. M., Balcells, M. E., Garcia-Basteiro, A. L., Cambau, E., Chaisson, R. E., Chee, C. B. E., Dalcolmo, M. P., Denholm, J. T., Erkens, C., Esposito, S., Farnia, P., Friedland, J. S., Graham, S., Hamada, Y., Harries, A. D., Kay, A. W., Kritski, A., Manga, S., Marais, B. J., Menzies, D., Ng, D., Petrone, L., Rendon, A., Silva, D. R., Schaaf, H. S., Skrahina, A., Sotgiu, G., Thwaites, G., Tiberi, S., Tukvadze, N., Zellweger, J.-P., D’Ambrosio, L., Centis, R. and Ong, C. W. M. (2022). Clinical standards for the diagnosis, treatment and prevention of TB infection. Int J Tuberc Lung Dis 26, 190–205, http://doi.org/10.5588/ijtld.21.0753.
Tunesi, S., Dû, D. L., Gualano, G., Millet, J.-P., Skrahin, A., Bothamley, G., Casas, X., Goletti, D., Lange, C., Musso, M., Palmieri, F., Pourcher, V., Rioux, C., Skrahina, A., Veziris, N., Viatushka, D., Jachym-Fréchet, M. and Guglielmetti, L. (2022). Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: a TBnet and ESGMYC study. Journal of Infection, http://doi.org/10.1016/j.jinf.2022.03.004.
Vongthilath-Moeung, R., Plojoux, J., Poncet, A., Renzi, G., Veziris, N., Schrenzel, J. and Janssens, J.-P. (2022). Nontuberculous Mycobacteria under Scrutiny in the Geneva Area (2015–2020). RES 101, 367–375, http://doi.org/10.1159/000520033.
Wetzstein, N., Drummer, A.-P., Bockey, A., Herrmann, E., Küpper-Tetzel, C. P., Graf, C., Koch, B., Goetsch, U., Vehreschild, M. J. G. T., Guglielmetti, L., Lange, B., Wichelhaus, T. A. and Stephan, C. (2022). Occurrence of extrapulmonary tuberculosis is associated with geographical origin: spatial characteristics of the Frankfurt TB cohort 2013–2018. Infection, http://doi.org/10.1007/s15010-022-01921-9.